



**Center for Vaccine Ethics & Policy (CVEP)**  
**Vaccines and Global Health: The Week in Review**  
**06 December 2025 :: Issue 825**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

## *Milestones, Perspectives*

.....  
.....

### ***Editor's Note:***

We have been organizing our coverage of US government actions involving vaccines, immunization and global health under a consolidated section below – [U.S. Immunization and Public Health Governance/Policy/ Funding](#). But we assessed that CDC's ACIP meeting this week – the content presented, the recommendations adopted, and the extraordinary response by the medical, scientific and policy communities – should lead this edition.

We have monitored ACIP meetings for more than 20 years, so we are "cautious but clear-eyed" in assessing that that we have reached a milestone. The ACIP is no longer functioning in its chartered independent, evidence-based, expert advisory role. It is a tragic, unnecessary, and quite probably irreversible milestone.

.....

## **Presidential Memorandum, ACIP Meeting Reports, Documentation**

### **[Aligning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries](#)**

***U.S. Presidential Memoranda, December 5, 2025***

In January 2025, the United States recommended vaccinating all children for 18 diseases, including COVID-19, making our country a high outlier in the number of vaccinations recommended for all children. Peer, developed countries recommend fewer childhood vaccinations — Denmark recommends vaccinations for just 10 diseases with serious morbidity or mortality risks; Japan recommends vaccinations for 14 diseases; and Germany recommends vaccinations for 15 diseases. Other current United States childhood vaccine recommendations also depart from policies in the majority of developed countries. **Study is warranted to ensure that Americans are receiving the best, scientifically-supported medical advice in the world.**

I hereby direct the Secretary of Health and Human Services and the Director of the Centers for Disease Control and Prevention **to review best practices from peer, developed countries for core childhood vaccination recommendations — vaccines recommended for all children — and the scientific evidence that informs those best practices, and, if they determine that those best practices are superior to current domestic recommendations, update the United States core childhood vaccine schedule to align with such scientific evidence and best practices from peer, developed countries while preserving access to vaccines currently available to Americans.**

This memorandum is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.

*MEMORANDUM FOR THE SECRETARY OF HEALTH AND HUMAN SERVICES; THE DIRECTOR OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION*

.....

## **ACIP - Meeting of the Advisory Committee on Immunization Practices**

December 4-5, 2025

- [Final ACIP December 4-5, 2025 Meeting Agenda \(posted 12-04-2025, 7pm\)](#)
- [Anticipated Votes](#)
- [ACIP Meeting Materials: December 04-05, 2025](#)
- [YouTube Live Stream Link 12-04-2025](#)
- [YouTube Live Stream Link 12-05-2025](#)
- [Written Public Comments](#)

## **ACIP Recommends Individual-Based Decision-Making for Hepatitis B Vaccine for Infants Born to Women Who Test Negative for the Virus**

*HHS, CDC Media Release*

ATLANTA — December 5, 2025 — The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) today **voted 8 to 3 to recommend individual-based decision-making for parents deciding whether to give the hepatitis B vaccine, including the birth dose, to infants born to women who test negative for the virus. For those infants not receiving the birth dose, ACIP suggested in its recommendation that the initial dose be administered no earlier than two months of age.**

Individual-based decision-making, known on the CDC immunization schedules as shared clinical decision-making, means that parents and health care providers should consider vaccine benefits, vaccine risks, and infection risks, and that parents consult with their health care provider and decide when or if their child will begin the hepatitis B vaccine series. The committee said parents and health care providers should consider whether there are infection risks such as a household member who has hepatitis B or frequent contact with persons who have emigrated from areas where hepatitis B is common.

**ACIP also voted to recommend that when evaluating the need for a subsequent hepatitis B vaccine dose in children, parents should consult with health care providers to decide whether to test antibody levels to hepatitis surface antigen to evaluate adequacy of protection through serology results.**

These recommendations on hepatitis B immunization maintain consistency of coverage for all payment mechanisms, including entitlement programs such as the Vaccines for Children Program, Children's Health Insurance Program, Medicaid, and Medicare, as well as insurance plans through the federal Health Insurance Marketplace. ACIP on September 19, 2025, voted to recommend that all pregnant women be tested for the hepatitis B virus, a test that is covered across all insurance programs.

Today's votes were preceded yesterday by presentations to ACIP on the hepatitis B disease burden, vaccine safety, and comparative nation immunization policies as well as briefings from representatives of the vaccine manufacturers.

A [presentation \[PDF, 1.41 MB\]](#) from Cynthia Nevison, Ph.D., on the decline of the hepatitis B disease burden since 1985 concluded that the universal birth dose contribution to acute case decline is likely small. It identified sharp declines in post-transfusion hepatitis B transmission due to advanced blood screening, improved dialysis practices, and needle exchange programs. It also acknowledged a 2019 study that found 57.9% of estimated births to women who test positive for the hepatitis B surface antigen were attributable to non-US-born women, mainly from high-endemicity countries. The study reported that 0.5% of pregnancies in the U.S. are to women who test positive for the hepatitis B surface antigen, which is the most significant risk to newborns for being infected with the virus.

ACIP Childhood/Adolescent Schedule Workgroup Chair Vicky Pebsworth, Ph.D., RN, [presented \[PDF, 487 KB\]](#) the policy context and historical and international comparison of the immunization schedule for hepatitis B. The United States' universal recommendation of the hepatitis B vaccine birth dose is an outlier among developed countries with low hepatitis B prevalence.

"The American people have benefited from the committee's well-informed, rigorous discussion about the appropriateness of a vaccination in the first few hours of life," said Deputy Secretary of Health and Human Services and CDC Acting Director Jim O'Neill.

**A recommendation from ACIP becomes part of the CDC immunization schedule once it is adopted by the CDC director.**

.....  
.....

**Responses to ACIP Presentations, Processes, Recommendations** [at Dec 6, 2025]

**[Statement from Leading Medical, Health and Patient Advocacy Groups on CDC Vaccine Meeting](#)**

December 5, 2025

**"We are deeply alarmed by the actions taken this week** by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP). **The apparent goal of this meeting was to sow doubt in vaccines rather than advance sound vaccine policy, and we will all pay a price for that.**

"This is a significant departure from the historic role ACIP has played in shaping vaccine policy in the United States. **Previously, we could expect science to drive decisions, experts to debate evidence, and consensus to lead to shared, clear recommendations. That is not the case with the current committee, and this change puts Americans' health at risk.**

"For example, ACIP's decision to downgrade the longstanding recommendation to vaccinate all newborns against hepatitis B at birth **will lead to more childhood hepatitis B infections, will lead to more chronic infections that will follow patients into adulthood, and will complicate vaccine access for children.** No new data was presented during the ACIP meeting to justify this change.

**"The evidence remains clear:** the hepatitis B birth dose is safe and an essential component in helping children develop immunity against a serious, potentially lifelong disease. In fact, since the U.S. implemented the hepatitis B birth dose in 1991, annual hepatitis B infections among infants and children have dropped 99%, from 16,000 to less than 20. This progress is directly attributable to timely vaccination.

"ACIP's actions will harm children, their families and the medical professionals who care for them. That is why we are joining together to speak up. American families deserve information grounded in science and clear, consistent guidance – not speculation intended to scare them.

**We urge the CDC leaders to reject ACIP's new recommendation and instead retain the current, evidence-based approach."**

American Academy of Pediatrics  
Academic Pediatric Association  
Alliance for Aging Research

American Association of Colleges of Nursing  
American Association of Colleges of Pharmacy  
American College of Emergency Physicians  
American College of Nurse Midwives  
American College of Obstetricians and Gynecologists  
American College of Physicians  
American Families for Vaccines  
American Medical Association  
American Medical Group Association (AMGA)  
American Pediatric Society  
American Public Health Association  
American Society for Clinical Laboratory Science (ASCLS)  
American Society for Meningitis Prevention  
America's Physician Groups  
Association of American Medical Colleges (AAMC)  
Association of State and Territorial Health Officials  
Caregiver Action Network  
Families Fighting Flu  
Families USA  
Georgetown University Center for Children and Families  
Global Liver Institute  
HealthHIV  
Hepatitis B Foundation  
Infectious Diseases Society for Obstetrics and Gynecology  
Infectious Diseases Society of America  
International Vaccine Access Center  
March of Dimes  
National Association of Pediatric Nurse Practitioners  
National Foundation for Infectious Diseases  
National Hispanic Health Foundation  
North American Society for Pediatric and Adolescent Gynecology  
Nurses Who Vaccinate  
Partnership to Fight Infectious Disease  
Pediatric Infectious Diseases Society  
Public Health Foundation  
Sepsis Alliance  
Society for Adolescent Health and Medicine  
Society for Maternal-Fetal Medicine  
Society for Pediatric Research  
Trusted Messenger Program  
Vaccinate Your Family  
Vaccine Integrity Project

:::::::

**American Medical Association (AMA)**

<https://www.ama-assn.org/press-center>

(Accessed 06 Dec 2025)

*Press Center - Latest News*

Dec 5, 2025

**[AMA statement on ACIP meeting](#)**

*Statement attributable to: Sandra Adamson Fryhofer, MD, Trustee, American Medical Association*

"The Advisory Committee on Immunization Practice's (ACIP) vote to weaken the birth-dose recommendation for the Hepatitis B vaccine **is reckless and undermines decades of public confidence in a proven, lifesaving vaccine. Today's action is not based on scientific evidence, disregards data supporting the effectiveness of the Hepatitis B vaccine, and creates confusion for parents about how best to protect their newborns.**

"Administering the birth dose is crucial for protecting children from both perinatal and early postnatal transmission of Hepatitis B virus—and preventing a lifelong condition that can lead to chronic liver disease, cirrhosis, liver cancer, and death.

**"The AMA calls on ACIP to make good on the Administration's promise to use gold standard science.** Families should be able to rely on the CDC for clear, evidence-based guidance when making important vaccination decisions for their children. **We urge the CDC to reject this recommendation and uphold its commitment to science and public health.** The consequences of failing to do so are too severe and the potential harm too great."

.....

### **American Public Health Association (APHA)**

<https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc>  
(Accessed 06 Dec 2025)

#### **ACIP decision to roll back universal Hepatitis B vaccine schedule recommendations will leave children vulnerable to unnecessary exposure and preventable illness**

December 05, 2025

The Advisory Committee on Immunization Practices' decision to change the universal Hepatitis B vaccine guidance increases the risk of infection for babies. This recommendation will leave children vulnerable to unnecessary exposure and preventable illness. **ACIP members failed to provide scientific evidence to show the long-term health benefits of delaying vaccination.** As a committee tasked with giving guidance to practitioners on the front lines of improving the health of all communities, this decision creates confusion instead of the needed evidence-based roadmap for families to make informed decisions about their child's health. The current vaccination schedule is doing what it is supposed to, which is taking a preventative approach to minimize infection and exposure to a dangerous infectious disease. Hepatitis B is a virus that causes serious health issues and delaying prevention will leave children unprotected, see others fall through the cracks of our health system, and increase the risk of the disease and its side effects on people throughout their lifespan.

#### **APHA Joins GW and Dozens of Public Health and Policy Experts Urging the CDC to Maintain Universal Newborn Hepatitis B Vaccination**

December 02, 2025

A public comment filed by 73 public health deans and scholars, along with the American Public Health Association - representing more than 23,000 individual members and numerous organizational members, **concludes that the evidence overwhelmingly supports maintaining the current schedule for immunizing children against the hepatitis B virus (HBV)...**

.....

### **Infectious Diseases Society of America (IDSA)**

<https://www.idsociety.org/>  
(Accessed 06 Dec 2025)

*News releases and statements*

#### **ACIP: Statement on Changes to HBV Birth Dose Vaccine Recommendation**

**The American Association for the Study of Liver Diseases (AASLD) and its undersigned partner organizations – the American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE), the Infectious Diseases Society of America (IDSA), and the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) –** are alarmed by the 8-3 vote by the Advisory Committee on Immunization Practices (ACIP) to abandon the recommendation to initiate universal hepatitis B vaccination immediately after birth. Relying on the hepatitis B status of the infant's mother to determine whether the birth dose is appropriate creates confusion and ambiguity for new parents, the community, and medical professionals when the evidence clearly supports the safety and effectiveness in providing lifetime protection of administering a universal birth dose after consultation between an infant's parents and their health care provider.

**As the leading societies dedicated to prevention, treatment and cure of liver diseases, we continue to strongly recommend that the hepatitis B vaccine be administered at birth to all infants as part of the validated three dose schedule** rather than delaying the first dose to two months for confirmed hepatitis B negative mothers and for the full vaccination series to be administered to all infants. We call on the Centers for Medicare & Medicaid Services to ensure that coverage for the birth dose without cost sharing remains in place and that states take steps to ensure access for all who choose the vaccine...

.....

#### **National Foundation for Infectious Diseases (NFID)**

<https://www.nfid.org/news-updates/>

(Accessed 06 Dec 2025)

*News and Updates*

#### **NFID Statement**

The National Foundation for Infectious Diseases (NFID) joins leading scientific, medical, and patient advocacy organizations in expressing alarm at the actions taken by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) at its meeting on December 4-5, 2025, including the decision to downgrade the longstanding recommendation to vaccinate all newborns against hepatitis B at birth.

**In oral and written comments submitted to ACIP, NFID strongly supported maintaining the current hepatitis B vaccination schedule, including the birth dose and broad adult vaccination.**

NFID joined the American Academy of Pediatrics and more than 40 other leading organizations in noting, "The evidence remains clear: the hepatitis B birth dose is safe and an essential component in helping children develop immunity against a serious, potentially lifelong disease. In fact, since the US implemented the hepatitis B birth dose in 1991, annual hepatitis B infections among infants and children have dropped 99%, from 16,000 to less than 20. This progress is directly attributable to timely vaccination."...

.....

#### **National Medical Association (NMA)**

<https://nmanet.org/blog/>

(Accessed 06 Dec 2025)

*Latest News*

#### **NMA Statement on ACIP Vote to Roll Back Universal Hepatitis B**

December 5, 2025



The National Medical Association is **adamantly opposed to the changes approved this week by the CDC's Advisory Committee on Immunization Practices (ACIP) that remove the universal recommendation for hepatitis B vaccination at birth.** These changes undermine decades of proven, evidence-based public health practice and place infants, especially Black newborns, who are disproportionately affected by hepatitis B, at unnecessary risk.

"The science on hepatitis B vaccination is clear, consistent and unchanged," said Dr. Roger A. Mitchell Jr., 126th president of the National Medical Association. **"Rolling back universal newborn vaccination creates confusion, invites misinformation and will cause preventable disease. This decision is misaligned with evidence, medical consensus and the needs of the communities most impacted."**

"This is one of the most successfully executed vaccination programs in U.S. public health history," said Dr. Dial Hewlett Jr., MD, FACP, FIDSA, Chair of the NMA Vaccine Task Force. "The data do not support changing course — particularly when Black infants already face higher risks of both exposure and barriers to prenatal screening."...

.....

### **Pediatric Infectious Diseases Society (PIDS)**

<https://pids.org/news-announcements/>

(Accessed 06 Dec 2025)

*News & Announcements*

Dec. 5, 2025

#### **PIDS Statement on ACIP Meeting's Impact on Public Health**

The Pediatric Infectious Diseases Society is deeply concerned by the Advisory Committee on Immunization Practices December meeting and its impact on public health in the United States.

The vote to change the recommendation on the birth dose of hepatitis B, absent new safety signals, data, or evidence, will increase the threat of avoidable acute and chronic liver disease. **This irresponsible change, along with additional misleading presentations during the meeting, will have massive consequences for children and their long-term health.**

**The inclusion of presentations by individuals who have made a career out of anti-vaccine attacks, misrepresented research, and leadership that interrupts normal procedure have turned ACIP into a liability for the safety of children.** Throughout the two-day meeting, committee members and presenters alike directed their comments to attending media in attempts to have anti-vaccine sentiment injected into coverage as reasonable discussion.

**PIDS supports the American Academy of Pediatrics vaccine schedule.** We will continue to advocate for strong science and discussion but will not support a biased group whose misleading of the public will result in children being harmed from vaccine preventable infections. **We also call on the acting CDC director to reject the outcome of their actions.**

.....

**PhRMA** [06 Dec 2025]

<http://www.phrma.org/>

December 5, 2025

#### **PhRMA Statement on December ACIP Meeting**



WASHINGTON, D.C. (December 5, 2025) – Pharmaceutical Research and Manufacturers of America (PhRMA) Chief Medical Officer Dr. Michael Ybarra issued the following statement on this week's Advisory Committee on Immunization Practices (ACIP) meeting:

"Ensuring Americans have access to safe and effective FDA-approved vaccines is vital. **The ACIP meeting this week introduced new confusion for health care professionals and the public – especially American parents.**

"The United States childhood immunization schedule has been developed over decades, grounded in evidence-based research to inform the appropriate dosing and timing of vaccination. **Changes, such as those discussed this week, without a transparent, science-driven process will have significant negative impacts on the prevention of dangerous diseases in children.**

**"ACIP's decision to stop recommending the universal birth dose for the hepatitis B vaccine was based on theory rather than sound evidence and puts the health of all Americans at risk.** Hepatitis B is a serious liver infection, and infants infected at birth have a 90% chance of developing chronic infection, which can lead to cirrhosis, liver cancer, liver failure and death. Hepatitis B is up to 100 times more infectious than HIV and can be passed to infants by an infected mother, family member or caregiver during pregnancy or birth, through cuts or bites or even by sharing personal items with someone who is infected.

"This is why the vaccine at birth is so important – it protects newborns immediately, when they need it most and before they can be exposed.

"Vaccines matter for every American and they are one of the best ways to prevent disease before it starts. We urge the administration to support continued access to vaccines so every American can protect themselves and their families."

.....

**BIO** [06 Dec 2025]

<https://www.bio.org/press-releases>

*Press Releases*

### **BIO Statement on December 2025 ACIP Meeting**

December 5, 2025

WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Head of Health Policy and Programs of the Biotechnology Innovation Organization (BIO) released the following statement on the December 2025 ACIP meeting.

"For decades, the CDC's Advisory Committee on Immunization Practices (ACIP) has been a shining example of America's leadership in scientific excellence and evidence-based decision-making.

**This year we've seen this once-transparent, apolitical process led by clinicians and infectious disease experts eroded meeting by meeting.**

**Adopting recommendations without rigorous analysis leaves American children and families vulnerable to deadly infectious diseases that have long been preventable because of vaccines. It sows confusion among patients and providers and undermines access.**

Today's decision to change the recommendation for hepatitis B vaccination for newborns, despite 35 years of progress toward eliminating the disease in children, will result in increased rates of hepatitis B, causing liver disease and cancer.

BIO urges ACIP to reaffirm its long-standing, transparent, balanced, evidence-based processes that support timely vaccine access and safeguard the nation's ability to prevent deadly infectious diseases."

.....

**Robert Wood Johnson Foundation** [to 06 Dec 2025]

<https://www.rwjf.org/en/about-rwjf/newsroom.html>

*Latest News and Highlights*

## Statement from Richard Besser, MD, on ACIP's Newborn Hepatitis B Vaccination Recommendation

Statement Dec-05-2025

PRINCETON—The Advisory Committee on Immunization Practices (ACIP) today has reversed its recommendation that all newborns receive a Hepatitis B vaccination. Dr. Richard Besser, president and CEO of the Robert Wood Johnson Foundation, released the following statement in response:

I used to look forward to ACIP meetings. I would listen as our nation's leading health experts presented and debated the best approaches to preventing disease and promoting health. But this vote is an example of why I now dread these meetings. **A committee of experts is now largely comprised of antivaccine champions.**

The committee's decision to reverse its longstanding recommendation that all newborns receive a Hepatitis B vaccine would be utterly shocking, were it not consistent with the anti-vaccine crusade Secretary Kennedy promised the nation. It flies in the face of the best scientific evidence and endangers our children. As a pediatrician for more than 30 years, I saw firsthand how vaccinating all newborns virtually eradicated Hepatitis B among children. But ACIP is now putting our children at needless risk of a dangerous and potentially fatal disease.

**This vote opens the door to a resurgence of Hepatitis B infections and is one more step in the administration's concerted efforts to dismantle the recommended childhood vaccination schedule.** If the committee continues to move in that direction, the health consequences will be devastating. More babies and young children will suffer from severe preventable illness, and some will die. More parents will have the profound anxiety and distress that comes with having a very sick child. Families will face major healthcare costs.

Those of us who care about children's health cannot allow this to happen. **Policymakers, physicians, and families must turn to reputable medical and public health groups for guidance, and health insurers should do the same for informing what vaccines they will cover.**

**The days of trusting ACIP and CDC for vaccine recommendations are gone.**

.....

### **Vaccine Integrity Project – CIDRAP**

<https://www.cidrap.umn.edu/vaccine-integrity-project>

### **Universal Hepatitis B Vaccination at Birth - Safety, Effectiveness, and Public Health Impact (Dec 2, 2025)**

*An independent evidence review of the safety, effectiveness and public health impact of universal hepatitis B vaccination at birth to compare current recommendations with a delayed first hepatitis vaccine dose at one month or more after birth.*

#### *Conclusion*

The reduction of HBV infection among infants and children in the United States over the past 40 years resulted from a series of evidence-based recommendations. Each sequential modification was based on the systematic review of vaccine safety, efficacy, and effectiveness; HBV incidence; gaps in coverage; and quality improvement programs. Improved coverage of infants at birth, in combination with completion of the full hepatitis B vaccine series, resulted in protection of children and was foundational for interrupting HBV transmission to the next generation and the reduction of hepatitis B-related infection, chronic liver disease, cancer, and death in the entire US population.

In this review, we evaluated vaccine safety and the potential individual and population-level benefits of delaying the first hepatitis B vaccination compared with vaccination at birth. The hepatitis vaccine has consistently been shown to be a safe vaccine, regardless of timing of vaccination. This analysis found no differences in short-term or long-term adverse events related to the birth dose compared with a delayed first dose. No benefits of vaccine efficacy, effectiveness, or long-term protection were identified in delaying the first dose compared with

vaccination at birth.

We also evaluated the potential population-level risks of delaying the first dose among infants born to HBsAg-negative mothers compared with those vaccinated at birth. This review found no evidence of any health benefit with delaying the birth dose and identified only risks related to changing current US recommendations for universal hepatitis B vaccination for all medically stable newborns weighing 2,000 grams or more within the first 24 hours of birth.

### ***Public Submission on ACIP Meeting, Dec 4-5, 2025***

#### **Comment from The Vaccine Integrity Project**

Posted by the Centers for Disease Control and Prevention on Nov 25, 2025

.....  
.....

### **Featured Journal Content**

#### **Economic evaluation of delaying the infant hepatitis B vaccination schedule**

Eric W. Hall, Prabhu Gounder, Heather Bradley, Noele P. Nelson

medRxiv 2025.11.24.25340907; PREPRINT doi: <https://doi.org/10.1101/2025.11.24.25340907>

##### ***Abstract***

**Introduction** Children who acquire hepatitis B virus (HBV) infection in early childhood through perinatal, household or community exposures are at highest risk of all age groups for experiencing chronic infection and premature death. Universal administration of hepatitis B (HepB) vaccine for all infants <24 hours of birth and completing the childhood series remains the cornerstone for HBV elimination efforts in the United States. We evaluated the health and economic impact of delaying HepB vaccination among U.S. infants.

**Methods** We constructed a Markov model to simulate lifetime health outcomes and costs for the 3,628,934 infants born in the United States in 2024 for HBV infections acquired up to age 18 years. The model incorporated hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) prevalence among birthing parents, percentage of pregnant parents tested for HBsAg during pregnancy or at delivery, vertical/perinatal and household/community HBV infection risks among children, and resulting sequelae from chronic infection. Eight delayed vaccination scenarios were evaluated in which the first HepB dose was given at 2 months, 7 months, 4 years, or 12 years, applied either only to infants born to HBsAg-negative birth parent or to both HBsAg-negative and HBsAg-unknown birthing parents. Outcomes included acute and chronic HBV infections, cirrhosis, hepatocellular carcinoma, HBV-related deaths, quality-adjusted life-years (QALYs), life-years, and total healthcare costs from the healthcare system perspective. We modeled scenarios with perfect and imperfect adherence to the HepB vaccination schedule, and scenarios with or without additional HBV screening costs for those with delayed receipt of HepB vaccine.

**Results** All delayed vaccination scenarios resulted in more infections, worse health outcomes, and higher costs than the current universal birth dose recommendation. Under perfect adherence, delaying HepB vaccination by 2 months for infants of HBsAg-negative parents led to an additional 90 acute infections, 75 chronic infections, 29 HBV-related deaths, with \$16.4 million in added costs for infants born during one year. Delaying to 12 years resulted in an additional 190 acute infections, 50 deaths, and nearly \$30 million in added costs. Delaying HepB vaccination to 12 years for infants of both HBsAg-negative and HBsAg-unknown parents resulted in an additional 2,351 acute infections, 744 deaths, and \$368 million in excess costs. Imperfect adherence to the vaccination schedule amplified all negative outcomes substantially. Incorporating pre-vaccination serologic screening for delayed schedules markedly increased total costs.

**Conclusions** Even brief delays in HepB vaccine initiation substantially increase HBV infections, adverse health outcomes, and health system costs. Our results quantify and demonstrate the

importance of the universal HepB birth dose in preventing perinatal and early childhood HBV transmission in the United States.



## Featured Journal Content

### New England Journal of Medicine Volume

Volume 393 No. 20 November 20, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

#### **A Threat to Evidence-Based Vaccine Policy and Public Health Security at the FDA**

Authors: Robert M. Califf, M.D., Andrew C. von Eschenbach, M.D., Michael A. Friedman, M.D., Brett P. Giroir, M.D., Scott Gottlieb, M.D., Margaret A. Hamburg, M.D., Jane E. Henney, M.D., David A. Kessler, M.D., Mark B. McClellan, M.D., Ph.D., Stephen M. Ostroff, M.D., Norman E. Sharpless, M.D., and Janet Woodcock, M.D. *Author Info & Affiliations*

Published December 3, 2025 DOI: 10.1056/NEJMp2517497

*Abstract*

Twelve former commissioners of the FDA express concern that the agency's recent moves will undermine a regulatory model designed to ensure vaccine safety, effectiveness, and availability.

*Text [Editor's text bolding]*

As former commissioners of the U.S. Food and Drug Administration (FDA) — who collectively guided the agency's oversight for more than 35 years, through myriad public health crises — we are committed to medical product safety and identifying new medical evidence with the speed, rigor, and openness that the public should expect. **We are deeply concerned by sweeping new FDA assertions about vaccine safety and proposals that would undermine a regulatory model designed to ensure that vaccines are safe, effective, and available when the public needs them most.**

The existing regulatory model builds public trust by encouraging open information exchange and rigorous, transparent scientific debate. Yet a memo sent last week to FDA staff will upend core policies governing vaccine development and updates.<sup>1</sup> These measures, and the unilateral way they are being imposed, undermine the public interest. They are the latest in a series of troubling changes at the FDA, including substantial departures of FDA staff, that could diminish both the FDA's strength and Americans' health and safety.

The memo (available at <https://www.biocentury.com/article/657740>) was written by Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research (CBER), who also serves as the agency's chief scientific officer, chief medical officer, and acting head of CBER's office of biostatistics, as well as overseeing the division responsible for vaccine review and approval. His memo characterizes the actions of FDA scientists who express concerns about agency processes or decisions to outside parties as "unethical" and "illegal." It calls for scientific debates to be kept within the agency "until they are ready to be made public," and instructs staff members who disagree with the new framework to "submit your resignation letters."

**The proposed guidelines would dramatically change vaccine regulation on the basis of a reinterpretation of selective evidence and by a process that breaks sharply with the norms that have anchored the FDA's globally respected scientific integrity.** If enacted, the framework would impede the ability to update vaccines to keep up with the natural evolution of respiratory viruses or changes in the prevalence of bacterial serotypes; it would also suppress

innovation and competition. The net effect would be to disadvantage the people the FDA exists to protect, including millions of Americans at high risk from serious infections.

**The new framework rejects the agency's long-standing reliance on "immunobridging" studies for well-understood vaccines with extensive safety data.** Using this approach, once a reliable correlation with effectiveness has been established, a vaccine's ability to stimulate the immune system to produce protective antibodies can serve as a surrogate for its efficacy in helping patients avoid infections and complications from rapidly evolving viruses such as SARS-CoV-2 and influenza. Because these viruses change frequently, repeating large-scale efficacy trials for every new seasonal strain is not feasible within the time needed to update the vaccines. Bridging studies have also been used to broaden vaccine protection to additional serotypes of bacteria.<sup>2</sup> The FDA continually updates the correlate strains used for immunobridging studies to ensure that vaccines remain safe and effective as threats evolve. Immunobridging studies have also been used for some new products, including the human papillomavirus vaccine that could largely eliminate cervical cancer.

**The proposed new directives are not small adjustments or coherent policy updates. They represent a major shift in the FDA's understanding of its job.** The memo states that "no amount of cell or humoral mediated immune surrogates" can justify approval of new or updated vaccines — logic that Prasad claims is implied by the lack of a full biosimilar pathway for vaccines. These arguments misrepresent both the science and the regulatory record, especially in the case of vaccines that target well-understood pathogens through an established mechanism of action.

**Abandoning the existing methods won't "elevate vaccine science," as the memo asserts. It will subject vaccines to a substantially higher and more subjective approval bar.** The proposed measures will slow the replacement of older products with better ones and will create potentially prohibitive expenses for new market entrants, especially small biotechnology companies. It's true that vaccines can generate substantial profits and that their complexity thwarts true generic competition, as the memo observes. But the proposed policy response would reduce competition and raise prices by demanding premarketing randomized clinical trials "for most new products."<sup>1,3</sup> Moreover, insisting on long, expensive outcomes studies for every updated formulation would delay the arrival of better-matched vaccines when new outbreaks emerge or when additional groups of patients could benefit. It is important to create a clear, science-driven, and well-reasoned pathway to approval; otherwise, innovators will have no reliable way to design their development programs. The people most affected by the FDA's proposed framework will include older Americans and those with weakened immune systems who rely most on the protection that timely and updated vaccines can offer.

**The new approach would also evade public transparency, including long-standing statutory and regulatory mechanisms that enable disagreements about benefit–risk balance, clinical trial end points, trial design, and data analysis to be aired in public.** Under the Administrative Procedure Act and the FDA's Good Guidance Practices, changes of this magnitude should be developed by guidance or regulation, with broad consultation within the agency, meaningful opportunity for public comment, and often public advisory-committee input. The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) exists precisely so that controversial scientific and policy questions receive independent expert review in public. **Yet FDA Commissioner Martin Makary's leadership team has said they intend to forgo advisory committee meetings for many major decisions, since they view these committees, which were established by bipartisan agreement in Congress decades ago, as a needlessly costly and burdensome check on their decision making.**<sup>4</sup>

**The stated motivation for these sweeping changes is the deaths of 10 children, which the FDA leadership asserts were caused by Covid-19 vaccines.** Any death that could be related to vaccination is tragic and warrants extensive investigation. Previously, all the cases reported to the



Centers for Disease Control and Prevention (CDC) and to the FDA had been carefully reviewed by FDA staff, who drew different conclusions. Adjudication of individual case reports is sensitive and subjective, and it relies on the rigor and goodwill of the people doing the evaluation. **The memo offered no explanation of the process and analyses that were used to reach the new retrospective judgment, nor did it indicate why that assessment should justify wholesale rewriting of vaccine regulation.**[1](#)

**The reanalysis relied on adverse event reports filed in the Vaccine Adverse Event Reporting System (VAERS)**, a passive postapproval surveillance system that collects unverified reports, from any source, of events occurring after vaccination. VAERS reports, by themselves, cannot be used to determine whether a vaccine caused a particular event. The system's primary purpose is to flag potential safety signals that must then be evaluated in carefully designed investigations. VAERS data have well-recognized challenges, including reporting bias and a lack of control groups.[5](#) The FDA therefore relies on many other data systems and methods as well, including medical record review, active surveillance programs, and independent peer review.

Yet accepting the review of VAERS reports as proof that “no fewer than 10” deaths were caused by Covid-19 vaccines, **Prasad concludes that the vaccines caused net harm in children — and then seeks to justify sweeping changes in regulatory standards for Americans at much higher risk for complications from many other infectious diseases.** All vaccines have risks and benefits, which are clarified by careful, transparent evaluation of evidence; FDA communications should present risks and benefits in a balanced manner. But the benefits and risks of many established vaccines are well understood, and imposing the new approval requirements without meaningful new evidence could make it impossible to keep up with evolving infectious threats.

**The memo asserts, incorrectly, that “we do not have reliable data” on the benefits of Covid vaccination in children.** Reasonable scientists should engage in open debate about how best to shape recommendations for children at lower risk for Covid-19, but substantial evidence shows that vaccination can reduce the risk of severe disease and hospitalization in many children and adolescents.

**Of course, the FDA must be willing to reexamine the standards for approval when new data warrant change. Such conversations, however, must also adhere to the process that gives FDA decisions their legitimacy: open deliberation and robust engagement with the agency's staff and the broader community.** Scientific disagreements should be respected. Demands for ideological alignment as a condition of employment are irreconcilable with an agency whose strength is the pluralism of its expert views. Americans' safety depends on a culture in which evidence is reviewed openly and staff can surface concerns, challenge leadership, and engage with external scientists without fear of reprisal.

The FDA has helped save millions of lives, sharpening its judgment as new evidence and better methods were developed, debated, and refined. Working at the FDA under both Republican and Democratic administrations, we saw up close how deeply the agency's staff believed in its public health mission.

**If the goal is to rebuild confidence, the answer is not to toss aside the basic rules of science, stifle argument and oversight, or supplant expert scientific inquiry for the unilateral decision making of a few individuals. It is to insist on open deliberation, solid evidence, and procedures the public can see and trust.**

.....  
.....  
.....

## WHO SAGE

### Meeting of the Strategic Advisory Group of Experts on Immunization, September 2025: Conclusions and recommendations

5 December 2025

#### *Overview*

The Strategic Advisory Group of Experts on Immunization (SAGE) met on 22-25 September 2025. This report summarizes their discussions, conclusions, and recommendations. All SAGE recommendations are made using evidence-based methods, the details of which are included in the background materials of the meeting.

.....  
.....

## WHO Pandemic Agreement

### Fourth meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement

1 – 5 December 2025

Hybrid, Geneva, Switzerland

Limited session recordings

### Statement at the fourth meeting of the open-ended Intergovernmental Working Group (IGWG 4) on the WHO Pandemic Agreement

*IFPAM Statement* 1 Dec 2025

On 1st December 2025 in Geneva, IFPMA delivered a statement at the fourth meeting of the open-ended Intergovernmental Working Group (IGWG 4) on the WHO Pandemic Agreement.

...The PABS should provide easy, rapid access to a broad set of pathogens for all researchers—public and private, North and South—while maintaining biosecurity. Industry participation depends less on new incentives and more on removing disincentives. Legal certainty during emergencies is critical; obligations must not be duplicated across frameworks.

Current proposals risk undermining preparedness by restricting access, adding bureaucracy, and increasing costs—discouraging R&D. Companies will continue accessing materials through multiple channels and partnerships, which is essential for innovation and rapid response.

The system should avoid complex sample-level traceability, focusing instead on biosafety standards. Highly structured traceability creates legal and operational uncertainty, complicates research, and diverts resources from collaboration.

We acknowledge the 20% real-time set-aside target in the Agreement. Industry participation requires flexibility in meeting obligations—through donations, tiered pricing, or voluntary licensing—to enable rapid, tailored responses. This approach strengthens contributions by enabling broader participation.

Rigid benefit-sharing obligations, IP restrictions, or mandatory financial contributions risk making engagement prohibitively costly, discouraging participation, and driving companies away. The most valuable contribution industry can make is building a pipeline of products ready for deployment. Currently, few vaccines and therapeutics target the highest-risk pathogens; without stimulating this pipeline, there will be no benefits to share.



As outlined, in our equitable access statements, depending on expertise and resources, companies can contribute through:

1. Strengthening innovation platforms for rapid deployment and expanding clinical trial networks globally.
2. Scaling production and ensuring supply continuity for repurposed medicines.
3. Enhancing manufacturing capacity via partnerships and voluntary technology transfer.
4. Supporting health-system and regulatory preparedness through financial and technical assistance for surveillance, trials, and workforce development.

These tools require enablers such as robust health systems, regulatory readiness, reduced trade barriers, and optimized delivery infrastructure.

The forthcoming PABS Annex will be a critical test of the WHO Pandemic Agreement's ability to deliver on its promise. Success depends on whether the Annex enables—not obstructs—innovation, partnership, and equitable access.

.....  
.....

## **World Bank: Gavi, Global Fund**

### **Gavi and World Bank Group Deepen Collaboration to Boost Health System Resilience and Regional Vaccine Manufacturing**

*World Bank Group and Gavi sign a new Memorandum of Understanding to strengthen immunization, primary healthcare and regional vaccine manufacturing*

Washington, D.C. / Geneva, 6 December 2025 – Gavi, the Vaccine Alliance (Gavi), and the World Bank Group are deepening their collaboration to strengthen financing for immunization and primary healthcare systems, while also supporting regional vaccine manufacturing in Africa. **Working together, the two organizations plan to mobilize at least US\$2 billion over the next five years in joint financing, aligned with country priorities...**

To support low- and lower middle-income countries as they transition from external support to long term sustainable financing, **Gavi and the World Bank Group will leverage new financing tools such as blended finance, buydowns, and guarantees, and work together in areas like public financial management...**

### **World Bank Group and the Global Fund Join Forces to Strengthen Health Systems and Expand Sustainable Health Financing**

*World Bank Group and Global Fund sign a new Memorandum of Understanding to strengthen primary healthcare and the fight against HIV, tuberculosis, and malaria*

Washington, D.C. / Geneva, 6 December 2025 – The World Bank Group and the Global Fund to Fight AIDS, Tuberculosis and Malaria have signed a Memorandum of Understanding (MoU) to **help developing countries build stronger, more resilient health systems and secure sustainable financing for primary health care and the fight against HIV, tuberculosis, and malaria.**

Working together, the two organizations plan to mobilize at least US\$2 billion over the next three years in joint financing, aligned with country priorities, to strengthen primary healthcare and expand access to essential services...

.....  
.....

## **Pharmacovigilance**

## [Artificial Intelligence in Pharmacovigilance](#)

Report - CIOMS Working Group XIV

2025 :: 204 pages <https://doi.org/10.56759/cdob6397>

This report on *Artificial intelligence in pharmacovigilance* addresses a rapidly emerging cross-disciplinary field that is at the intersection of pharmacovigilance, computer science, mathematics, regulation, law, medicine, human rights, psychology and social science. Consequently, just as with medicinal products, it is important to establish the approved indications, posology, side effects, and warnings and precautions for use of artificial intelligence in pharmacovigilance. The latter must be clearly defined and understood by many people from different backgrounds to propel research and practical implementation in an effective, safe and responsible manner. The diverse pool includes professionals, researchers, and decision makers working in pharmacovigilance in biopharmaceutical industry, regulatory authorities, and academia. It also includes software vendors that develop artificial intelligence solutions for pharmacovigilance, including signal management and all aspects of Individual Case Safety Report processing. This report provides the requisite terminology and conceptual understanding to actively engage in this space, either by participating in the applied scientific research and public discourse, or by performing evaluations and making decisions at their respective organisations.

.....  
.....  
.....

## **Polio – PHEIC**

[Polio this week](#) [03 December 2025]

*Headlines [Selected]*

### **:: Gavi and GPEI Boards Meet to Boost Immunization and Drive Polio to Zero**

The Boards of Gavi and the Global Polio Eradication Initiative met for their second joint session, focusing on one shared mission: reaching the world's zero-dose and under-immunized children — and keeping the world on track to finish polio for good. [More](#).

### **:: Global Polio Certification Experts Meet in Geneva to Assess Progress and Next Steps**

The Global Commission for the Certification of Poliomyelitis Eradication (GCC) met in Geneva last week to review the worldwide polio situation, including regional vaccination and surveillance trends. The experts examined current strategies — including the GPEI Action Plan 2026 — and discussed how to accelerate eradication while strengthening protection in polio-free regions.

### **:: Integration in Action: Polio Team Helps Stop Latest Ebola Outbreak in DRC**

The Democratic Republic of the Congo has officially declared the end of its recent Ebola outbreak — and the polio eradication network played a key role. Working with the Ministry of Health, WHO deployed experienced polio experts to strengthen surveillance, logistics, contact tracing and community engagement in affected areas of Kasai Province. A perfect example of how polio infrastructure protects far more than polio alone. [More](#).

### ***Summary of new polioviruses this week:***

- :: Angola: one cVDPV2 case
- :: Chad: two cVDPV2-positive environmental samples
- :: DR Congo: two cVDPV2 cases
- :: Papua New Guinea: seven cVDPV2-positive environmental samples

.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [U.S. Immunization and Public Health Governance/Policy/Funding](#)  
:: [Organization Announcements](#)  
:: [Journal Watch](#)  
:: [Pre-Print Servers](#)  
:: [Think Tanks](#)  
:: [Public Consultations/Call for Inputs/Call for Papers](#)

:::::::  
:::::::

**WHO & Regional Offices** [06 Dec 2025]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

5 December 2025

[\*\*Meeting of the Strategic Advisory Group of Experts on Immunization, September 2025: Conclusions and recommendations\*\*](#)

:::::::

**WHO Vaccines and Immunization [IVB]**

[https://www.who.int/health-topics/vaccines-and-immunization#tab=tab\\_1](https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1)

*News*

5 December 2025

[\*\*Meeting of the Strategic Advisory Group of Experts on Immunization, September 2025: Conclusions and recommendations\*\*](#)

:::::::

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**WHO African Region AFRO**

:: 05 December 2025

[\*\*Rift Valley Fever in Senegal: On the Frontline to Protect Communities\*\*](#)

:: 04 December 2025

[\*\*African footballers star in Kick Out Polio campaign ahead of AFCON 2025\*\*](#)

:: 04 December 2025

[\*\*The hope carried by young Madagascans in the fight against antimicrobial resistance\*\*](#)

**WHO Region of the Americas PAHO**

:: 5 Dec 2025

[\*\*PAHO launches Regional Alliance to accelerate HIV elimination in the Americas\*\*](#)

The new platform aims to strengthen political and technical coordination and expand access to innovations to reduce new infections by 90% and achieve zero AIDS-related deaths by 2030. Washington, D.C., December 5, 2025 (PAHO) – The Pan American Health Organization (PAHO) today launched the Regional Alliance for HIV Elimination in the Americas, a...

**WHO South-East Asia Region SEARO**

*No new digest content identified.*

**WHO European Region EURO**

:: 2 December 2025 *News release*

[\*\*WHO launches tuberculosis screening campaign for refugees living in Bulgaria\*\*](#)

## **WHO Eastern Mediterranean Region EMRO**

:: [\*\*Strengthening vector control capacity: training of trainers on WHO susceptibility bioassays for mosquito vectors\*\*](#)

4 December 2025

:: [\*\*HIV infections rise in Pakistan; WHO and UNAIDS call to action\*\*](#)

1 December 2025

## **WHO Western Pacific Region**

:: 4 December 2025 *Media release*

[\*\*Stronger and healthier islands: Reaching every child with life-saving vaccines\*\*](#)

:: 4 December 2025 *Media release*

[\*\*Getting ready for the next pandemic: Western Pacific countries and areas carry out a key r...\*\*](#)

.....

## **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

*No new reports identified.*

## **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

[\*\*5 December 2025 | Broader transmission of mpox due to clade Ib MPXV – Global situation\*\*](#)

[\*\*5 December 2025 | Avian Influenza A\(H5N5\) - United States of America\*\*](#)

[\*\*1 December 2025 | Ebola virus disease - Democratic Republic of the Congo\*\*](#)

...On 1 December 2025, the Ministry of Health (MoH) of the Democratic Republic of the Congo (DRC) declared the end of the Ebola virus disease (EVD) outbreak which had been declared on 4 September 2025. The end was declared after two consecutive incubation periods (a total of 42 days) since the last person confirmed with EVD tested negative for the virus and was discharged on 19 October 2025...

.....

## **Weekly Epidemiological Record**

Vol. 100, No. 49, pp. 605–626 5 December 2025

<https://www.who.int/publications/journals/weekly-epidemiological-record>

:: Meeting of the Strategic Advisory Group of Experts on Immunization, September 2025: conclusions and recommendations

.....

## **New WHO Publications**

<https://www.who.int/publications>

*Selected*

5 December 2025

[\*\*Tracking universal health coverage: 2025 global monitoring report\*\*](#)

*Overview*

The window to 2030, the SDG target year, is closing. Without accelerated and sustained progress, hard-won UHC gains risk being lost. Using revised and improved UHC indicators the report presents the latest available UHC data and concludes with a call to shared action.

5 December 2025

**[Meeting of the Strategic Advisory Group of Experts on Immunization, September 2025: Conclusions and recommendations](#)**

4 December 2025

**[Decarbonizing the healthcare supply chain strategic actions for health systems](#)**

4 December 2025

**[World malaria report 2025](#)**

2 December 2025

**[Framework and toolkit for infection prevention and control outbreak preparedness, readiness and response](#)**

2 December 2025

**[Strategic plan for coronavirus disease threat management: advancing integration, sustainability, and...](#)**

1 December 2025

**[Global strategy on digital health 2020-2027](#)**

1 December 2025

**[Responding to the health financing emergency: immediate measures and longer-term shifts](#)**

.....  
.....  
.....

## **Africa**

**Africa CDC** [06 Dec 2025]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

*Press Releases*

**[Africa CDC Study Explores SMS Messaging to Strengthen TB Treatment](#)**

3 December 2025

*Press Releases*

**[Ebola Outbreak in the DRC Declared Over](#)**

2 December 2025

*Press Releases*

**[Ethiopia Launches Fourth National Plan to Combat Antimicrobial Resistance](#)**

1 December 2025

.....  
.....

## **China – CDC+**

<http://www.chinacdc.cn/en/>

### **National Health Commission of the People's Republic of China** [06 Dec 2025]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

### **National Medical Products Administration – PRC** [06 Dec 2025]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

## **China CDC**

### **CCDC Weekly Reports: Current Volume (7)**

#### **2025-12-05 / No. 49**

[PDF of this issue](#)

- [Editorial: Letter from the New Editor-in-Chief](#)
- [Preplanned Studies: Outbreak of Chikungunya Virus with Aedes albopictus-Adaptive Mutations — Guangdong Province, China, 2025](#)
- [Outbreak Reports: The First Imported Case of Chikungunya Virus Infection — Anhui Province, China, 2025](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, October 2025\\*](#)

.....

.....

## **Europe**

### **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

[News/Updates/Reports/Publications \[Selected\]](#)

[Two cases of Middle East respiratory syndrome \(MERS\) in travellers returning to France from the Arabian Peninsula](#)

5 Dec 2025

[ECDC defines strategies to fight avian and swine flu in humans](#)

4 Dec 2025

### **European Medicines Agency [EMA]**

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

*No new digest content identified.*

.....

.....

## **India**

### **National Centre for Disease Control**

Directorate General of Health Services, Ministry of Health & Family Welfare  
Announcements  
No new digest content identified.

.....  
.....  
.....

### **U.S. Immunization and Public Health Governance/Policy/Funding**

*Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive.*

### **Executive Branch - White House, State, HHS, FDA, CDC+**

#### **White House**

*Presidential Actions – Executive Orders; Memoranda; Proclamations*

#### **[Aligning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries](#)**

*Presidential Memoranda, December 5, 2025*

#### **Department of State**

*Press Releases - Selected*

*Press Statement*

#### **[Continuing to Deliver on the America First Global Health Strategy with the Signing of the United States-Rwanda Bilateral Health Cooperation Memorandum of Understanding](#)**

Thomas "Tommy" Pigott December 5, 2025

...Under the arrangement, working with Congress, the United States intends to provide up to \$158 million over the next five years to support Rwanda's efforts to combat HIV/AIDS, malaria, and other infectious diseases, and to bolster disease surveillance and outbreak response. In turn, the Government of Rwanda plans to increase its own domestic health investment by \$70 million, taking on greater financial responsibility as U.S. support is gradually reduced over the years...

*Remarks*

#### **[Secretary of State Marco Rubio with Kenyan President William Ruto at the Signing of a Health Framework of Cooperation](#)**

Marco Rubio December 4, 2025 Benjamin Franklin Room Washington, D.C.

*Fact Sheet*

#### **[America First Global Health Strategy – Bilateral Agreements on Global Health Cooperation](#)**

December 4, 2025

As outlined in the America First Global Health Strategy, the United States will sign multi-year Bilateral Agreements on Global Health Cooperation with dozens of countries receiving U.S. health assistance in the coming weeks. These landmark agreements will advance a comprehensive and shared vision directly between the United States and recipient country governments for continued future cooperation on global health issues. The agreements will also maximize the impact of our global health assistance and strengthen our bilateral relationships while simultaneously saving millions of lives, stopping the spread of diseases globally, and helping countries move toward more resilient and durable health systems...

Each agreement will contain important and innovative provisions that facilitate long-term sustainability such as:



- **Commodities:** The procurement of commodities will be transitioned from the U.S. government to partner governments gradually over the established period of the agreement. The United States has committed to covering 100 percent of frontline healthcare workers and commodities for the next fiscal year and will work with countries to co-invest in these efforts over time.
- **Frontline Health Workers:** Frontline health workers currently funded by the U.S. government will be mapped to the cadres of health workers that can be employed by partner governments, and those cadres of health workers will be transitioned to the partner government payroll over a multi-year period as jointly agreed to.
- **Data Systems:** Funding will support the scale up of partner governments' health data systems to ensure key programmatic data for HIV/AIDS, TB, malaria, polio, and disease outbreaks can be tracked at scale long-term.
- **Co-Investment:** Partner governments will increase their domestic health expenditures over the agreement period, a critical step in ensuring partner governments have the resources they need to sustain their health response long-term without support from the U.S. government.
- **Performance Incentives and Transition Assistance:** U.S. government financial support will be linked to countries' ability to meet or exceed key health metrics with financial incentives for countries who exceed those metrics...

*Press Statement*

**[Advancing the America First Global Health Strategy Through Landmark Bilateral Agreements on Global Health Cooperation](#)**

Marco Rubio December 4, 2025

**HHS**

*Press Room - Selected*

**[ACIP Recommends Individual-Based Decision-Making for Hepatitis B Vaccine for Infants Born to Women Who Test Negative for the Virus](#)**

ATLANTA — December 5, 2025

**[HHS Protects Parents' Rights in Children's Health Decisions](#)**

WASHINGTON — DECEMBER 3, 2025 — The U.S. Department of Health and Human Services (HHS) today announced strong actions to protect the rights of parents within the practice of pediatric medicine. HHS opened an investigation into a complaint that a Midwestern school illegally vaccinated a child with a federally provided vaccine without the parents' consent by ignoring a religious exemption submitted under a state law. HHS also issued a [Dear Colleague letter \[PDF, 265 KB\]](#) reminding health care providers about federal law requiring them to provide parents access to their children's health information. In addition, the Department directed the Health Resources and Services Administration (HRSA) to add a grant requirement stating that all funding recipients must comply with all applicable federal and state parental-consent laws for any services or care provided to minors at HRSA-supported health centers as a condition of receiving Health Center Program funds.

"Today, we are putting pediatric medical professionals on notice: you cannot sideline parents," said Health and Human Services Secretary Robert F. Kennedy, Jr. "When providers ignore parental consent, violate exemptions to vaccine mandates, or keep parents in the dark about their children's care, we will act decisively. We will use every tool at our disposal to protect families and restore accountability."...

**NIH** [to 06 Dec 2025]

<http://www.nih.gov/>

*News Releases*

*No new digest content identified [last news release on November 13, 2025]*

## **FDA**

*Press Announcements - Selected*

*FDA News Releases*

### **December 3, 2025 - FDA Announces Leadership Appointments at Center for Drug Evaluation and Research**

The U.S. Food and Drug Administration (FDA) today announced that Tracy Beth Høeg, M.D., Ph.D., has been appointed acting director of the Center for Drug Evaluation and Research (CDER). A physician and epidemiologist, Dr. Høeg was a Visiting Scholar at the Massachusetts Institute of Technology Sloan School of Management and practiced physical and interventional spine and sports medicine before joining the FDA as Senior Advisor for Clinical Sciences in the Office of the Commissioner and the Center for Biologics Evaluation and Research (CBER)...

### **December 1, 2025 - FDA Expands Artificial Intelligence Capabilities with Agentic AI Deployment**

The U.S. Food and Drug Administration today announced the deployment of agentic AI capabilities for all agency employees. Agentic AI capabilities will enable the creation of more complex AI workflows — harnessing various AI models — to assist with multi-step tasks.

Agentic AI refers to advanced artificial intelligence systems designed to achieve specific goals by planning, reasoning, and executing multi-step actions. These systems incorporate built-in guidelines — including human oversight — to ensure reliable outcomes. The tool is entirely optional for FDA staff and is used voluntarily.

"We are diligently expanding our use of AI to put the best possible tools in the hands of our reviewers, scientists and investigators," said FDA Commissioner Marty Makary, M.D., M.P.H. "There has never been a better moment in agency history to modernize with tools that can radically improve our ability to accelerate more cures and meaningful treatments."...

## **FDA CBER**

*What's New for Biologics*

*No new digest content identified.*

## **FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]**

*Advisory Committee Calendar*

***No future meetings posted.***

## **FDA Pediatric Advisory Committee Meeting**

*Advisory Committee Calendar*

***No future meetings posted.***

## **CDC**

<http://www.cdc.gov/media/index.html>

*Latest News - Selected*

### **ACIP Recommends Individual-Based Decision-Making for Hepatitis B Vaccine for Infants Born to Women Who Test Negative for the Virus**

December 5, 2025

*[See HHS above for full text]*

## **CDC – Immunization Safety Office (ISO)**

<https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html>

*No new digest content identified.*

## **ACIP**

### **2026 Meetings Schedule**

- February 25-26
- June 24-25
- October 21-22

### **Meeting of the Advisory Committee on Immunization Practices**

December 4-5, 2025

- Final ACIP December 4-5, 2025 Meeting Agenda (posted 12-04-2025, 7pm)
- Anticipated Votes
- ACIP Meeting Materials: December 04-05, 2025
- YouTube Live Stream Link 12-04-2025
- YouTube Live Stream Link 12-05-2025
- Written Public Comments

### **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2025.html>

**December 4, 2025 / No. 39**

[PDF of this issue](#)

:: Human-to-Human Rabies Transmission via Solid Organ Transplantation from a Donor with Undiagnosed Rabies — United States, October 2024–February 2025

### **National Vaccine Program Committee (NVAC)**

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

***No 2025 meeting dates posted.***

### **Advisory Commission on Childhood Vaccines (ACCV)**

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

***Next ACCV Meeting – TBD [To be re-scheduled from original date January 29, 2025]***

.....

### **NSF**

*News*

*No new digest content identified.*

.....

### **U.S. Congress**

#### **House of Representatives**

*No new digest content identified.*

#### **U.S. Senate**

#### ***Senate Health, Education, Labor, and Pensions (HELP) Committee***

*No new digest content identified.*

.....

### **Supreme Court, Federal & Appellate Courts**

*No new digest content identified.*

.....

.....

## U.S. States

### Illinois

#### [Gov. Pritzker Signs Landmark Bill to Protect and Expand Vaccine Access for Illinoisans](#)

*HB 767 codifies access to life-saving immunizations as the federal government abandons science*

News – Tuesday, December 2, 2025

CHICAGO — Today, Governor JB Pritzker joined state officials, bill sponsors, and public health experts to sign HB 767. **The legislation expands and codifies Governor Pritzker's Executive Order 2025-04, which empowers the Illinois Department of Public Health to offer transparent, science-based vaccine guidelines through its expert Immunization Advisory Committee (IAC), while also expanding vaccine access.**

"While RFK Jr. and his QAnon-inspired colleagues spread conspiracy theories and dangerous misinformation about vaccines, Illinois is stepping up to protect the health of our people," said **Governor JB Pritzker. "It is vitally important that Illinois families can get trusted advice about vaccines, guided by experts and established research.** With this new law, we will be able to respond swiftly to any dangerous or anti-science actions at the federal level — and ensure Illinoisans stay protected. More affordable and accessible health care for all Illinoisans prevents illness and saves lives."

Governor Pritzker's signature on HB 767 ensures Illinoisans will receive clear, science-based immunization guidelines as federal recommendations grow more contradictory and confusing. **While the federal government abandons its critical role in public health leadership, the Pritzker Administration is stepping up to protect the health and well-being of all Illinoisans...**

For decades, state health officials and practitioners could rely on science-based vaccine recommendations and schedules from the independent Advisory Committee on Immunization Practices (ACIP) board. Additionally, recommendations from the ACIP are required to be covered by insurance providers. **However, the Trump Administration has essentially dismantled the ACIP, firing members and appointing vaccine sceptics whose beliefs are not backed by science. These actions have led to the erosion of trust, caused confusion regarding vaccine guidelines, and threatened access to life-saving vaccines.**

#### ***Key Provisions of HB 767:***

- **Create and Publish Vaccine Guidelines for Illinoisans:** IDPH will create and publish vaccine guidelines for Illinoisans based on experts from the Illinois Immunization Advisory Committee (IAC). Previously, Illinois and other states relied on the federal government through ACIP for this resource.
- **Codifies the Structure of the IAC** [Illinois Immunization Advisory Committee], including Checks and Balances: The bill specifies the membership and functions of the IAC and out of a commitment to ensuring all recommendations are rooted in science, provides a mechanism for the committee to override Director recommendations.
- **Require Insurance Companies to Cover Vaccines Recommended by IDPH:** State-regulated health insurance issuers are required to cover vaccines and related administration based on IDPH recommendations, even if they extend beyond ACIP schedules.
- **Expand Youth Vaccine Access in Pharmacies:** Reduce the minimum age from 7 to 3 for pharmacist administration of certain vaccines — making them more accessible.

This bill is aligned with the newly launched Illinois Vaccine Access Program (IVAP). Overseen by IDPH, this state-funded initiative supports local health departments with the option to directly order certain vaccines at no cost for Illinoisans who may otherwise lack access. IVAP's 2025-2026 COVID-19 Vaccine

Initiative is focused on reducing barriers to immunization for several key populations, including young children...

.....  
.....  
.....

## **U.S. Medical Societies, Health Organizations**

### **American Academy of Family Physicians (AAFP)**

<https://www.aafp.org/news/media-center.html>

(Accessed 06 Dec 2025)

*No new digest content identified.*

### **American Academy of Pediatrics (AAP)**

<https://www.aap.org/en/news-room/news-releases-from-the-aap/>

(Accessed 06 Dec 2025)

*News*

#### **Hepatitis B Immunization is Critical to Protect All Newborns**

December 5, 2025

#### **Statement from Leading Medical, Health and Patient Advocacy Groups on CDC Vaccine Meeting**

December 5, 2025

### **American College of Physicians (ACP)**

<https://www.acponline.org/more-acp-news>

(Accessed 06 Dec 2025)

*ACP News*

#### **Statement from leading medical, health and patient advocacy groups on CDC vaccine meeting**

12/05/25

#### **ACP encourages adults to get vaccinated during National Influenza Vaccination Week**

12/04/25

*I.M. Matters Weekly*

### **America's Health Insurance Plans (AHIP)**

<https://www.ahip.org/news>

(Accessed 06 Dec 2025)

*News*

*No new digest content identified.*

### **American Geriatrics Society (AGS)**

<https://www.americangeriatrics.org/media-center>

(Accessed 06 Dec 2025)

*Recent Press Releases*

*No new digest content identified.*

### **American Medical Association (AMA)**

<https://www.ama-assn.org/press-center>

(Accessed 06 Dec 2025)

*Press Center - Latest News*

Dec 5, 2025

**[AMA statement on ACIP meeting](#)**

### **American Osteopathic Association (AOA)**

<https://osteopathic.org/news/>

(Accessed 06 Dec 2025)

*Latest News*

*No new digest content identified.*

### **American Public Health Association (APHA)**

[https://www.apha.org/news-and-media/news-](https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc)

[releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc](https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc)

(Accessed 06 Dec 2025)

**[ACIP decision to roll back universal Hepatitis B vaccine schedule recommendations will leave children vulnerable to unnecessary exposure and preventable illness](#)**

December 05, 2025

The Advisory Committee on Immunization Practices' decision to change the universal Hepatitis B vaccine guidance increases the risk of infection for babies. This recommendation will leave children vulnerable to unnecessary exposure and preventable illness.

**[APHA Joins GW and Dozens of Public Health and Policy Experts Urging the CDC to Maintain Universal Newborn Hepatitis B Vaccination](#)**

December 02, 2025

A public comment filed by 73 public health deans and scholars, along with the American Public Health Association - representing more than 23,000 individual members and numerous organizational members, concludes that the evidence overwhelmingly supports maintaining the current schedule for immunizing children against the hepatitis B virus (HBV).

### **Infectious Diseases Society of America (IDSA)**

<https://www.idsociety.org/>

(Accessed 06 Dec 2025)

*News releases and statements*

*News*

**[Statement from Leading Medical, Health and Patient Advocacy Groups on CDC Vaccine Meeting](#)**

*News*

**[ACIP: Statement on Changes to HBV Birth Dose Vaccine Recommendation](#)**

The American Association for the Study of Liver Diseases (AASLD) and its undersigned partner organizations – the American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE), the Infectious Diseases Society of America (IDSA), and the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) – are alarmed by the 8-3 vote by the Advisory Committee on Immunization

Practices (ACIP) to abandon the recommendation to initiate universal hepatitis B vaccination immediately after birth. Relying on the hepatitis B status of the infant's mother to determine whether the birth dose is appropriate creates confusion and ambiguity for new parents, the community, and medical professionals when the evidence clearly supports the safety and effectiveness in providing lifetime protection of administering a universal birth dose after consultation between an infant's parents and their health care provider.

As the leading societies dedicated to prevention, treatment and cure of liver diseases, we continue to strongly recommend that the hepatitis B vaccine be administered at birth to all infants as part of the validated three dose schedule rather than delaying the first dose to two months for confirmed hepatitis B negative mothers and for the full vaccination series to be administered to all infants. We call on the Centers for Medicare & Medicaid Services to ensure that coverage for the birth dose without cost sharing remains in place and that states take steps to ensure access for all who choose the vaccine...

### **Massachusetts Public Health Alliance (MPHA)**

<https://mapublichealth.org/press-room/>

(Accessed 06 Dec 2025)

*Press Room*

*No new digest content identified.*

### **National Foundation for Infectious Diseases (NFID)**

<https://www.nfid.org/news-updates/>

(Accessed 06 Dec 2025)

*News and Updates*

December 6, 2025

#### **[Statement on CDC ACIP Meeting](#)**

The National Foundation for Infectious Diseases and leading scientific and medical organizations express alarm at actions by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP)

December 3, 2025

#### **[NFID Calls for Evidence-Based Guidance as Many People Skip Life-Saving Respiratory Vaccines](#)**

Survey reveals misconceptions about vaccines and declining vaccination rates

### **National Medical Association (NMA)**

<https://nmanet.org/blog/>

(Accessed 06 Dec 2025)

*Latest News*

#### **[NMA Statement on ACIP Vote to Roll Back Universal Hepatitis B](#)**

December 5, 2025

The National Medical Association is adamantly opposed to the changes approved this week by the CDC's Advisory Committee on Immunization Practices (ACIP) that remove the universal recommendation for hepatitis B vaccination at birth. These changes undermine decades of proven, evidence-based public health practice and place infants, especially Black newborns, who are disproportionately affected by hepatitis B, at unnecessary risk.

"The science on hepatitis B vaccination is clear, consistent and unchanged," said Dr. Roger A. Mitchell Jr., 126th president of the National Medical Association. "Rolling back universal newborn vaccination creates confusion, invites misinformation and will cause preventable disease. This decision is misaligned with evidence, medical consensus and the needs of the communities most impacted."



"This is one of the most successfully executed vaccination programs in U.S. public health history," said Dr. Dial Hewlett Jr., MD, FACP, FIDSA, Chair of the NMA Vaccine Task Force. "The data do not support changing course — particularly when Black infants already face higher risks of both exposure and barriers to prenatal screening."...

### **Pediatric Infectious Diseases Society (PIDS)**

<https://pids.org/news-announcements/>

(Accessed 06 Dec 2025)

News & Announcements

Dec. 5, 2025

#### **[PIDS Statement on ACIP Meeting's Impact on Public Health](#)**

Dec. 2, 2025

#### **[PIDS Rejects Claims of Harm Due to Tested, Approved Vaccines](#)**

PIDS strongly rejects the claim by US Food and Drug Administration that vaccine regulatory processes are lax and that there is evidence that COVID-19 vaccines for children are unsafe or...

### **Society for Healthcare Epidemiology of America (SHEA)**

<https://shea-online.org/news/>

(Accessed 06 Dec 2025)

#### **[APIC and SHEA Announce Joint Healthcare Infection Prevention Advisory Group \(HIPAG\) December 02, 2025](#)**

Washington, D.C. — The Association for Professionals in Infection Control and Epidemiology (APIC) and the Society for Healthcare Epidemiology of America (SHEA) have announced a new collaborative initiative, the Healthcare Infection Prevention Advisory Group (HIPAG), to address infection prevention priorities of national importance.

The elimination of the CDC's Healthcare Infection Control Practices Advisory Committee (HICPAC) has created gaps in coordinated, multidisciplinary alignment on infection prevention and control and antimicrobial stewardship issues, raising concerns about potential variation and inconsistencies in organizational policies and clinical practice. HIPAG was established to help fill these gaps and ensure continuity by offering timely, evidence-informed advisory expertise that supports the needs of participating organizations and the broader healthcare community.

This initiative reflects a shared commitment to enhancing transparency, inclusivity, and scientific rigor in national infection prevention discussions.

APIC and SHEA believe that this group, which will include invited representative experts across medical societies, healthcare organizations, public health, and patient advocacy groups, will help maintain a unified approach to infection prevention as new challenges and emerging threats continue to evolve...

### **Society for Maternal-Fetal Medicine (SMFM)**

<https://www.smfm.org/>

(Accessed 06 Dec 2025)

News

*No new digest content identified.*

.....  
.....

### **Civil Society – Individuals, Organizations, Institutions**

.....

**Autism Science Foundation**

<https://autismsciencefoundation.org/>

*No new digest content identified.*

.....

**Brookings** [to 06 Dec 2025]

<http://www.brookings.edu/>

*Regulatory Policy*

**[Tracking regulatory changes in the second Trump administration](#)**

*No new digest content identified.*

.....

**Kaiser Family Foundation/KFF** [06 Dec 2025]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

**[Recent Changes in Children's Vaccination Rates by Race and Ethnicity](#)**

Dec 3, 2025 *Issue Brief*

Data show that children's vaccination rates, including MMR and seasonal flu vaccines, have declined in recent years largely due to decreases in vaccinations among White and Asian children. At the same time, and despite the declines among White and Asian children, Black and AIAN children remain least likely to have received recommended childhood vaccinations and the MMR vaccine specifically.

**[Global COVID-19 Tracker](#)**

Dec 1, 2025 *Issue Brief*

This tracker provides data on global COVID-19 cases and deaths by country, region, and income-level. Additionally, the tracker reports current closure, economic, and health system policy responses to the COVID-19 pandemic globally. This tracker will be updated as new data are available.

**[KFF Tracker: U.S. Pledges to Upcoming Multilateral Health Replenishments](#)**

Dec 1, 2025 *Fact Sheet*

This KFF tracker provides up to date information on U.S. pledges thus far to four multilateral health replenishments (the Pandemic Fund, WHO, Gavi, and the Global Fund) and U.S. government support to date.

.....

**O'Neill Institute – Health Care Litigation Tracker** [Georgetown University]

<https://litigationtracker.law.georgetown.edu/>

*No new digest content identified.*

.....

**Vaccine Integrity Project – CIDRAP**

<https://www.cidrap.umn.edu/vaccine-integrity-project>

**[Universal Hepatitis B Vaccination at Birth - Safety, Effectiveness, and Public Health Impact \(Dec 2, 2025\)](#)**

*An independent evidence review of the safety, effectiveness and public health impact of universal hepatitis B vaccination at birth to compare current recommendations with a delayed first hepatitis vaccine dose at one month or more after birth.*

#### *Conclusion*

The reduction of HBV infection among infants and children in the United States over the past 40 years resulted from a series of evidence-based recommendations. Each sequential modification was based on the systematic review of vaccine safety, efficacy, and effectiveness; HBV incidence; gaps in coverage; and quality improvement programs. Improved coverage of infants at birth, in combination with completion of the full hepatitis B vaccine series, resulted in protection of children and was foundational for interrupting HBV transmission to the next generation and the reduction of hepatitis B-related infection, chronic liver disease, cancer, and death in the entire US population.

In this review, we evaluated vaccine safety and the potential individual and population-level benefits of delaying the first hepatitis B vaccination compared with vaccination at birth. The hepatitis vaccine has consistently been shown to be a safe vaccine, regardless of timing of vaccination. This analysis found no differences in short-term or long-term adverse events related to the birth dose compared with a delayed first dose. No benefits of vaccine efficacy, effectiveness, or long-term protection were identified in delaying the first dose compared with vaccination at birth.

We also evaluated the potential population-level risks of delaying the first dose among infants born to HBsAg-negative mothers compared with those vaccinated at birth. This review found no evidence of any health benefit with delaying the birth dose and identified only risks related to changing current US recommendations for universal hepatitis B vaccination for all medically stable newborns weighing 2,000 grams or more within the first 24 hours of birth.

#### ***Public Submission on ACIP Meeting, Dec 4-5, 2025***

##### **[Comment from The Vaccine Integrity Project](#)**

Posted by the Centers for Disease Control and Prevention on Nov 25, 2025

.....

#### **Paul Offit, MD – *Beyond the Noise***

Substack: <https://pauloffit.substack.com/>

*No new digest content identified.*

.....

.....

#### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

#### ***Organization Announcements***

**Paul G. Allen Frontiers Group** [06 Dec 2025]

<https://alleninstitute.org/news-press/>

News

*No new digest content identified.*

**BMGF - Gates Foundation** [06 Dec 2025]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

*Press release Dec 06, 2025*

**Gates Foundation and Qatar Fund for Development Launch Milestone Partnership to Improve Health, Food Security, and Economic Opportunity**

*New catalytic funding will expand access to health, climate-resilient agriculture, and access to education across Africa and South Asia*

DOHA, QATAR (December 6, 2025) – On the sidelines of the Doha Forum, the Gates Foundation and the Qatar Fund for Development (QFFD) announced a five-year strategic partnership, committing US\$500 million to drive accelerated progress in global health, climate-resilient agriculture, and education. The goal of the partnership is to help improve outcomes for mothers, children, and young people across Africa, South Asia, and Southeast Asia...

*Press release Dec 03, 2025*

**With Child Deaths Projected to Rise for the First Time This Century, Gates Foundation Urges Global Leaders to Target Scarce Resources Where They Save the Most Lives**

*New Goalkeepers Report models impact of global health funding cuts, offers roadmap of best buys and most effective investments to slow this reversal*

SEATTLE (December 3, 2025) – The number of children dying before their 5th birthday is projected to rise for the first time this century, reversing decades of global progress, according to new data published today in the Gates Foundation's 2025 Goalkeepers Report.

In 2024, 4.6 million children died before their 5th birthday. According to modeling in the report, conducted by the Institute for Health Metrics and Evaluation (IHME), that number is projected to rise by just over 200,000—to an estimated 4.8 million children this year. At the same time, global development assistance for health fell sharply this year—26.9% below 2024 levels. Beyond this year's drastic funding cuts, countries face mounting debt, fragile health systems, and the risk of losing hard-won gains against diseases like malaria, HIV, and polio.

The report, *We Can't Stop at Almost*, warns that if global health funding cuts persist, up to 16 million more children could die by 2045. It offers a roadmap for how targeted investments in proven solutions and next generation innovations can save millions of children's lives, preventing a reversal in progress in today's constrained budget environment....

**CARB-X** [06 Dec 2025]

<https://carb-x.org/>

News

12.04.2025 |

**CARB-X to support ProtonDx for evaluation of a blood-based diagnostic method to identify lower-respiratory tract infections**

CARB-X has awarded ProtonDx US\$1M in seed funding to evaluate whether blood can be used as a suitable sample type for diagnosing pediatric lower-respiratory tract infections (LRTIs).

**Chan Zuckerberg Initiative** [06 Dec 2025]

<https://chanzuckerberg.com/newsroom/>

*Newsroom*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [06 Dec 2025]

<http://cepi.net/>

*CEPI News, Blog*

*Blog*

**Disease outbreak survivors are key to future preparedness**

The BSI - Biospecimen Sourcing Initiative (BSI) - is a new global resource that aims to facilitate the timely, coordinated, and ethical sourcing of biospecimens—such as blood—in an infectious disease outbreak.

*News*

**First volunteer receives Lassa fever vaccine in cutting-edge Oxford trial**

3 Dec 2025

- The Oxford Vaccine Group has vaccinated the first volunteer in a first-in-human trial of its Lassa vaccine
- The CEPI-funded trial is being conducted in Oxford, with a second phase 1 trial due to start in Ghana early next year
- The World Health Organization (WHO) has identified Lassa fever as a priority pathogen in urgent need of research and development because it poses a significant public health risk due to its epidemic potential

*News*

**Korea steps up pandemic response with \$18.9m investment in CEPI**

3 Dec 2025

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 06 Dec 2025]

<https://cioms.ch/>

*News; Publications; Events*

**Artificial Intelligence in Pharmacovigilance**

Report - CIOMS Working Group XIV

2025 :: 204 pages <https://doi.org/10.56759/cdob6397>

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [06 Dec 2025]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**DNDI – Drugs for Neglected Diseases initiative** [06 Dec 2025]

<https://dndi.org/press/press-releases/>

*Press Releases*

*No new digest content identified.*

**Duke Global Health Innovation Center** [06 Dec 2025]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [06 Dec 2025]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

01 December 2025

[\*\*Strengthening the HIV response through African leadership and global collaboration\*\*](#)

**Emory Vaccine Center** [06 Dec 2025]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [06 Dec 2025]

<http://www.euvaccine.eu/>

*News*

[\*\*EVI holds team retreat in the Netherlands\*\*](#)

**Fondation Merieux** [06 Dec 2025]

<http://www.fondation-merieux.org/>

*Actualités*

*No new digest content identified.*

**Gates Medical Research Institute** [06 Dec 2025]

<https://www.gatesmri.org/news>

*The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.*

*News: Articles and Publications*

*No new digest content identified.*

**Gavi** [to 06 Dec 2025]

<https://www.gavi.org/>

*News Releases*

4 December 2025

[\*\*A new era dawns for Gavi, as Board underlines strategic shift towards country ownership and increased support for the most vulnerable\*\*](#)

3 December 2025

[\*\*Gavi and Global Polio Eradication Initiative Boards convene for second joint session\*\*](#)

3 December 2025

[\*\*Morocco pledges US\\$ 5 million to Gavi, debuts as a donor to global immunisation efforts\*\*](#)

**GE2P2 Global Foundation** [06 Dec 2025]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

*Digests*

:: [Vaccines and Global Health: The Week in Review - Current edition](#)

:: [Informed Consent: A Monthly Review – May 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 12 Nov 2025](#)

:: [Genomics, Gene Editing, Convergent Biosciences: Governance, Ethics, Policy, Practice – A Monthly Review – Nov 2025](#)

**GHIT Fund** [06 Dec 2025]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 06 Dec 2025]

<https://www.theglobalfund.org/en/news/>

*News Releases*

**[World Bank Group and the Global Fund Join Forces to Strengthen Health Systems and Expand Sustainable Health Financing](#)**

*World Bank Group and Global Fund sign a new Memorandum of Understanding to strengthen primary healthcare and the fight against HIV, tuberculosis, and malaria*

06 December 2025

Washington, D.C. / Geneva – The World Bank Group and the Global Fund to Fight AIDS, Tuberculosis and Malaria have signed a Memorandum of Understanding (MoU) to help developing countries build stronger, more resilient health systems and secure sustainable financing for primary health care and the fight against HIV, tuberculosis, and malaria...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [06 Dec 2025]

<https://www.glopid-r.org/>

*News & Events*

**[Highlights from the GloPID-R General Assembly](#)**

December 2, 2025

**Hilleman Laboratories** [06 Dec 2025]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [06 Dec 2025]

<https://www.hhmi.org/news>

*Press Room*

**[Scientists Capture First Detailed Look Inside Droplet-like Structures of Compacted DNA](#)**



A team of researchers led by HHMI Investigator Michael Rosen has captured the most detailed images yet of the molecules in chromatin condensates — droplet-like structures of compacted DNA.  
Dec 4, 2025

**Human Immunome Project [nee Human Vaccines Project]** [06 Dec 2025]

<https://www.humanimmunomeproject.org/>

News

*No new digest content identified.*

**IAVI** [06 Dec 2025]

<https://www.iavi.org/>

Press Releases, Features

December 4, 2025

**Fierce optimism despite challenging circumstances**

*Reflecting on nearly three decades of IAVI Report and the future of HIV vaccine research.*

By Kristen Kresge Abboud

**INSERM** [06 Dec 2025]

<https://www.inserm.fr/en/home/>

Press Releases

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

*No new digest content identified.*

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]** [to 06 Dec 2025]

<https://www.ich.org/>

News/Pubs/Press Releases [Selected]

Ongoing Public Consultations		^
>	Q3E EWG	Guideline for Extractables and Leachables
>	E20 EWG	Adaptive Designs for Clinical Trials
>	E22 EWG	General Considerations for Patient Preference Studies

<https://www.ich.org/page/public-consultations>

**ICRC** [to 06 Dec 2025]

<https://www.icrc.org/en/news>

News

Article 04-12-2025

**Mozambique: ICRC responds to pressing humanitarian needs**

About 250'000 people have been displaced in the last year because of the armed conflict in northern Mozambique.

**IFFIm** [06 Dec 2025]

<http://www.iffim.org/>

*Press Releases/Announcements*

**[Sierra Leone looks forward to "massive reduction" in cervical cancer after vaccine campaign](#)**

01 Dec 2025

An ambitious November campaign to protect a million girls with the HPV vaccine could mark a historic inflection point in Sierra Leone's journey to elimination of the all-too-common cancer

**IFRC** [to 06 Dec 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press releases*

*Press release 05/12/2025*

**[As Ebola in DRC declared over, IFRC calls for investment in community-based surveillance](#)**

**IPPS - International Pandemic Preparedness Secretariat** [06 Dec 2025]

<https://ippsecretariat.org/news/>

*News*

*No new digest content identified.*

**Institut Pasteur** [06 Dec 2025]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 06 Dec 2025]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*news*

04 December 2025 - 4 min read

**[New agreement to promote policy, research and practice-relevant knowledge](#)**

The International Science Council (ISC) and the International Association of Universities (IAU) have formalized a new partnership through a Memorandum of Understanding designed to strengthen collaboration on shared priorities at the intersection of science, policy and higher education.

*blog*

03 December 2025 - 6 min read

**[Trust in science: Ethical responsibilities for scientists and universities](#)**

In this commentary, Robert French outlines the ethical responsibilities of scientists and universities in sustaining trust in science.

*news*

03 December 2025 - 6 min read

### [Advancing coordinated reform in publishing and research assessment](#)

In November, key actors engaged in publishing and research-assessment reform convened in Pisa, Italy, to explore practical opportunities for joint action.

### **International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News, Resources*

*No new digest content identified.*

### **IVAC** [06 Dec 2025]


<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*U.S. Measles Tracker*

### [Tracking Measles Cases in the U.S.](#)

Updated December 5, 2025



### **IVI** [06 Dec 2025]

<http://www.ivi.int/>

*IVI News & Announcements*

[IVI and the Regionalized Vaccine Manufacturing Collaborative sign partnership agreement to advance regional vaccine manufacturing and equity](#)

3 December 2025 — The International Vaccine Institute (IVI) and the Regionalized Vaccine Manufacturing Collaborative (RVMC), hosted by CEPI, signed a Memorandum of Understanding today to deepen cooperation in strengthening the resilience and sustainability of vaccine manufacturing and supply chains across Asia, Africa, Latin America, and other regions. The agreement reflects a shared commitment to expanding equitable vaccine access and supporting countries in developing manufacturing capacity for routine immunization and outbreak preparedness...

**Johns Hopkins Center for Health Security** [06 Dec 2025]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

**Robert Wood Johnson Foundation** [to 06 Dec 2025]

<https://www.rwjf.org/en/about-rwjf/newsroom.html>

*Latest News and Highlights*

**[Statement from Richard Besser, MD, on ACIP's Newborn Hepatitis B Vaccination Recommendation](#)**

*Statement* Dec-05-2025

**MSF/Médecins Sans Frontières** [to 06 Dec 2025]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*South Sudan*

**[MSF healthcare facility hit in an airstrike in South Sudan](#)**

*Press Release* 4 Dec 2025

*Pakistan*

**[Tuberculosis patients find strength and care in Baldia, Pakistan](#)**

*Project Update* 4 Dec 2025

*Honduras*

**[MSF concludes Arbovirus prevention project in Tegucigalpa](#)**

*Project Update* 2 Dec 2025

**National Academy of Medicine** - USA [to 06 Dec 2025]

<https://nam.edu/programs/>

*News, Stories, Insights*

*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]**- USA [to 06 Dec 2025]

<https://www.nationalacademies.org/newsroom>

*News*

**[National Academies and Kuwait Foundation for the Advancement of Sciences Partner on Precision Medicine Workshops](#)**

*Feature Story* Dec 4, 2025

**PATH** [06 Dec 2025]

<https://www.path.org/media-center/Newsroom> [Selected]

### **PATH's MenAfriVac wins Prix Galien Bridges Award for Public Sector Innovation**

December 5, 2025 by PATH

PATH is honored to announce that the Galien Foundation has awarded the 2025 Prix Galien Bridges Award for Public Sector Innovation to MenAfriVac—the groundbreaking conjugate vaccine developed through the Meningitis Vaccine Project (MVP), a partnership led by PATH and the World Health Organization (WHO).

### **PATH and Africa Clinical Research Network partner to optimize execution of clinical trials in Africa**

December 3, 2025 by PATH

The Africa Clinical Research Network (ACRN) and PATH have formalized a partnership through a memorandum of understanding aimed at strengthening the execution of clinical trials and supporting long-term research capacity across Africa. The collaboration brings together PATH's technical expertise in clinical trial design and implementation with ACRN's Africa-led coordination platform, which connects research sites, investigators, and national programs across the continent...

**Sabin Vaccine Institute** [06 Dec 2025]

<https://www.sabin.org/press/>  
*Latest News & Press Releases*

### **Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response**

December 4, 2025

Washington, D.C. – The Sabin Vaccine Institute (Sabin) has sent more than 640 doses of its investigational cAd3-Marburg Vaccine to Ethiopia to support the country's response to its first-ever outbreak of Marburg virus disease. Marburg is a highly contagious hemorrhagic fever disease and can have a high case fatality rate of up to 88%. There are currently no licensed vaccines or treatments for Marburg.

Soon after Marburg was confirmed as the virus causing a hemorrhagic fever outbreak in Ethiopia's southern region, the Ethiopia Ministry of Health engaged Sabin and the U.S. government to request access to Sabin's investigational cAd3-Marburg Vaccine. The U.S. government approved this request. The Biomedical Advanced Research and Development Authority (BARDA), part of U.S. Department of Health and Human Services' Administration for Strategic Preparedness and Response (ASPR), funds the development and manufacture of Sabin's investigational vaccine candidate.

Sabin and the Ethiopia Ministry of Health have entered into a clinical trial agreement under which Sabin is providing BARDA-funded investigational cAd3-Marburg Vaccine doses for a two-cohort Phase 2, rapid response, open-label, randomized trial to assess safety, efficacy, and immunogenicity. Under this approved protocol, Cohort A is limited to high-risk health care and front-line workers or individuals who have had direct contact with infected persons within 21 days, the incubation period for Marburg virus disease. All other health care and front-line workers and contacts will be randomized in Cohort B, some receiving vaccine on Day 1 and others on Day 22 of the trial...

**UNAIDS** [06 Dec 2025]

<http://www.unaids.org/en>  
*News, Stories, Updates*  
*Press Release*

### **UNAIDS welcomes new agreement between the United States and Kenya to advance progress to end AIDS and strengthen health systems**

WASHINGTON/GENEVA, 4 December 2025—UNAIDS welcomes the signing of a landmark five-year Health Framework for Cooperation between the United States Government and the Government of Kenya to advance strengthened cooperation on HIV and other key areas of health.

The agreement was signed today in Washington DC by US Secretary of State Marco Rubio and President of Kenya William Ruto. It builds on decades of shared commitment between the US and Kenya through the US President's Emergency Plan for AIDS Relief (PEPFAR) and represents a renewed demonstration of shared solidarity, co-investment, self-reliant systems and resolve to save lives, reduce new HIV infections, and advance progress towards ending AIDS in Kenya.

The agreement aligns with UNAIDS global targets—including ensuring that 95% of people living with HIV know their status, 95% of those diagnosed receive sustained, quality treatment, and 95% of those on treatment are virally suppressed. It also supports the goal of reducing new HIV infections and AIDS-related deaths by 90% by 2030, compared to 2010 levels.

In the signing, the US commits to provide up to US\$ 1.6 billion over five years to support technical assistance, capacity building, and financial resources to reinforce Kenya's national HIV and health response. In turn, Kenya has committed to provide around US\$ 850 million in domestic funding to sustain and enhance the agreement.

UNAIDS considers today's agreement between the US and Kenya a milestone in the future of global health cooperation, bringing renewed momentum to advance Kenya's outstanding response to HIV and US leadership in the global HIV response.

**As noted by Secretary Rubio, the agreement with Kenya is the first of 50 planned bilateral agreements with partner countries in coming weeks...**

*Press Statement*

**UNAIDS, WHO and the Global Fund call for political leadership, international cooperation, and community-led approaches at a joint World AIDS Day event**

GENEVA, 1 December 2025—UNAIDS, WHO and the Global Fund brought together members of communities, civil society organizations and government representatives to commemorate this year's World AIDS Day at an event at UNAIDS headquarters in Geneva, Switzerland.

"Our progress is fragile and is now under threat due to the collapse of international assistance and the regression on human rights," said Winnie Byanyima, UNAIDS Executive Director. In 2025, a historic funding crisis threatened to unravel decades of progress. HIV prevention services were severely disrupted. *Community-led services, vital to reaching marginalized populations were also deprioritized while the rise in punitive laws criminalizing same-sex relationships, gender identity, and drug use amplified the crisis, making HIV services inaccessible to many...*

**UNICEF** [to 06 Dec 2025]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements [Selected]*

*Press release* 05 December 2025

**UNICEF Executive Director calls for urgent action and sustained investments for children in South Sudan**

JUBA, 6 December, 2025 -, UNICEF Executive Director Catherine Russell today concluded a visit to South Sudan, urging the Government and the international community to step up efforts to protect children's lives amid escalating conflict, climate shocks and mass displacement in the world's youngest country. Russell...

*Remarks* 05 December 2025

**Millions of children in Southeast Asia affected by relentless climate-related disasters**

GENEVA, 05 December 2025 -, "Over the past months and in recent weeks, children across five countries in Southeast Asia – Indonesia, Viet Nam, Thailand, the Philippines, and Malaysia – have faced the devastating effects of typhoons, floods and storms. "They are waking up in evacuation shelters.

They're drinking un...

**Unitaid** [06 Dec 2025]

<https://unitaid.org/>

*Press Releases*

*News releases*

**[Lenacapavir use kicks off in South Africa and Brazil through Unitaid partnership with Wits RHI and Fiocruz](#)**

01 December 2025

**Vaccine Equity Cooperative [nee Initiative]** [06 Dec 2025]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccine Confidence Project** [06 Dec 2025]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [06 Dec 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [06 Dec 2025]

<https://wellcome.org/news/all>

*News. Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 06 Dec 2025]

<https://www.wistar.org/news/press-releases>

*Press Releases*

December 3, 2025

**[The Wistar Institute Announces Recruitment of Vincent Wu to Join Vaccine & Immunotherapy Center as Caspar Wistar Fellow](#)**

Interdisciplinary scientist brings expertise in molecular biology and bioinformatics to study HIV reservoir, where dormant virus hides

**World Bank** [to 06 Dec 2025]

<http://www.worldbank.org/en/news/all>

*News [Selected]*

**[Gavi and World Bank Group Deepen Collaboration to Boost Health System Resilience and Regional Vaccine Manufacturing](#)**

World Bank Group and Gavi sign a new Memorandum of Understanding to strengthen immunization,



primary healthcare and regional vaccine manufacturing Washington, D.C. / Geneva, 6 December 2025 – Gavi...

Date: December 06, 2025 Type: Press Release

### **Progress Toward 1.5 Billion Health Care Goal Advances as Countries Adopt National Health Compacts**

Reforms focus on expanding primary care, improving affordability, and supporting job-rich growth TOKYO, Dec. 6, 2025 — Countries and partners today reported continued progress toward the World Bank Group's...

Date: December 06, 2025 Type: Press Release

### **World Bank Group and the Global Fund Join Forces to Strengthen Health Systems and Expand Sustainable Health Financing**

World Bank Group and Global Fund sign a new Memorandum of Understanding to strengthen primary healthcare and the fight against HIV, tuberculosis, and malaria Washington, D.C. / Geneva, 6 December 2025 –...

Date: December 06, 2025 Type: Press Release

### **Tracking Universal Health Coverage (UHC): 2025 Global Monitoring Report**

Download Report | Access Dataset

Date: December 05, 2025 Type: Publication

### **GCC Economies Demonstrate Resilience, Advance Diversification, and Accelerate Digital Transformation**

World Bank's Gulf Economic Update reviews a decade of economic diversification, highlights strong momentum in recent years, and a surge in AI-driven digital transformation WASHINGTON, December 4, 2025...

Date: December 04, 2025 Type: Press Release

### **Developing Countries' Debt Outflows Hit 50-Year High During 2022-2024**

World Bank Was Largest Provider of Net New Financing to 78 Most Vulnerable Countries WASHINGTON, December 3, 2025—Developing countries paid out \$741 billion more in principal and interest on their...

Date: December 03, 2025 Type: Press Release

### **WFPHA: World Federation of Public Health Associations [06 Dec 2025]**

<https://www.wfpha.org/>

*Blog, Events*

*No new digest content identified.*

### **World Medical Association [WMA] [to 06 Sep 025]**

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

*No new digest content identified.*

### **World Organisation for Animal Health [OIE] [06 Dec 2025]**

<https://www.oie.int/>

*Press Releases, Statements*

*No new digest announcements identified.*

.....  
.....

**ARM [Alliance for Regenerative Medicine]** [06 Dec 2025]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest announcements identified.*

**BIO** [06 Dec 2025]

<https://www.bio.org/press-releases>

*Press Releases*

**[BIO Statement on December 2025 ACIP Meeting](#)**

December 5, 2025

**DCVMN – Developing Country Vaccine Manufacturers Network** [06 Dec 2025]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest announcements identified.*

**ICBA – International Council of Biotechnology Associations** [06 Dec 2025]

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

**IFPMA** [06 Dec 2025]

<https://ifpma.org/>

*News & Resources*

*Statement 1 Dec 2025*

**[Statement at the fourth meeting of the open-ended Intergovernmental Working Group \(IGWG 4\) on the WHO Pandemic Agreement](#)**

On 1st December 2025 in Geneva, IFPMA delivered a statement at the fourth meeting of the open-ended Intergovernmental Working Group (IGWG 4) on the WHO Pandemic Agreement.

**International Alliance of Patients' Organizations – IAPO** [06 Dec 2025]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

**[Single Global Development of Generic and Biosimilar Medicines: a cornerstone of Patient Access \(December 2025\)](#)**

A research report resulting from a collaboration between the University of Maryland and University of Michigan (USA) delivers a critical set of recommendations emphasizing the urgent need for policies that foster single global development of off patent medicines.

### **The IGBA CEO Advisory Committee: Patient Access, Industry Value, and Global Cooperation in a Reshaping World (December 2025)**

On 20 November, the CEO Advisory Committee of the International Generic and Biosimilar Medicines Association (IGBA) convened to discuss how the generics and biosimilars sector can continue to deliver on its mission—ensuring affordable, safe, effective and quality-assured therapies for patients— in a shifting international landscape.

**PhRMA** [06 Dec 2025]

<http://www.phrma.org/>

*Press Releases*

December 5, 2025

### **PhRMA Statement on December ACIP Meeting**

.....

.....

### ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

*We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.*

#### **AstraZeneca**

*Press Releases - No new digest announcements identified.*

#### **Bavarian Nordic**

*Latest News - No new digest announcements identified.*

#### **BioCubaFarma – Cuba**

*Últimas Noticias - No new digest announcements identified.*

#### **Biological E**

*News - No new digest announcements identified.*

#### **BioNTech**

*Press Releases*

3 December 2025

### **BioNTech Achieves Minimum Condition in CureVac Exchange Offer**

#### **Boehringer**

*Press Releases - No new digest announcements identified.*

#### **CanSinoBIO**

*News - Website not responding at inquiry.*

#### **CIGB**

*Latest News - No new digest announcements identified.*

#### **CinnaGen**

Recent News - No new digest announcements identified.

**Clover Biopharmaceuticals – China**

News - No new digest announcements identified.

**CSL Sequirus**

News Releases - No new digest announcements identified.

**Curevac**

News

December 3, 2025

[BioNTech Achieves Minimum Condition in CureVac Exchange Offer](#)

**Dailchi Sankyo**

Press Releases - No new digest announcements identified.

**Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

**GSK**

Press releases for media - No new digest announcements identified.

**EuBiologics, S Korea**

News - No new digest announcements identified.

**HIPRA**

Press releases - No new digest announcements identified.

**IMBCAMS, China**

Home - Website not responding at inquiry.

**JNJ Innovative Medicine [Janssen]**

Press Releases - No new digest announcements identified.

**Merck**

News releases - No new digest announcements identified.

**Nanogen**

News - No new digest announcements identified.

**Novartis**

News - No new digest announcements identified.

**Novavax**

Press Releases - No new digest announcements identified.

**Pfizer**

Recent Press Releases - No new digest announcements identified.

**R-Pharm**

<https://rpharm-us.com/index.php>

*[No news or media page identified]*

## **Sanofi Pasteur**

[Press Releases](#)

### **[Sanofi completes acquisition of Vicebio](#)**

Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd ("Vicebio"). This acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio's 'Molecular Clamp' technology.

The acquired vaccine candidate complements Sanofi's position in respiratory vaccines. It enables Sanofi to offer increased physician and patient choice in RSV and HMPV by adding a non-mRNA vaccine to its pipeline.

## **Serum Institute**

[News & Announcements](#) - No new digest announcements identified.

## **Sinopharm/WIBPBIBP**

[News](#) - No new digest announcements identified.

## **Sinovac**

[Press Releases](#) - No new digest announcements identified.

## **SK Biosciences**

[Press Releases](#) - No new digest announcements identified.

## **Takeda**

[Newsroom](#) - No new digest announcements identified.

## **Valneva**

[Press Releases](#) - No new digest announcements identified.

## **WestVac Biopharma**

[Media](#) - No new digest announcements identified.

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) *[No News/Announcements page identified]*

.....  
.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

## ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 27, Number 11: E769-822 November 2025

<https://journalofethics.ama-assn.org/issue/electronic-health-record-evolution>

#### ***Electronic Health Record Evolution***

Patients' charts once hung at the feet of their hospital beds, and their purpose was to serve as the record of care for a particular patient. Now, electronic health records (EHRs) have several functions and serve many stakeholders' interests. This theme issue investigates which kinds of work EHRs should do—and for whom—and whose interests EHRs should serve when information is entered, organized, reviewed, responded to, extracted, or amended. This issue also investigates which values should inform EHR stewardship and innovation decisions and from whose perspectives the stakes of those decisions should be framed.

### **American Journal of Human Genetics**

Nov 06, 2025 Volume 112 Issue 11 p2563-2814

<https://www.cell.com/ajhg/current>

#### ***This month in The Journal***

Paul W. Hook, Alyson B. Barnes

Rare diseases affect more than 5% of the population in the United States. Classically, rare diseases are diagnosed through a phenotype-first approach in which individuals with distinct clinical features undergo genetic testing to identify the underlying genetic basis of their disorder. This approach can lead to ascertainment bias toward individuals with more severe or well-characterized phenotypes, leaving many affected individuals without a diagnosis. A genotype-first approach could increase diagnoses and provide insight into the phenotypic spectrum and prevalence of rare diseases, but this approach is difficult to apply at scale.

[Reviewed earlier]

### **American Journal of Infection Control**

November 2025 Volume 53 Issue 11 p1131-1242

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

November 2025 Volume 69 Issue 5

<https://www.ajpmonline.org/current>

Reviewed earlier]

### **American Journal of Public Health**

November 2025 115(11)

<http://ajph.aphapublications.org/toc/ajph/current>

Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 113 | Issue 5 November 2025

<https://www.ajtmh.org/view/journals/tpmd/113/3/tpmd.113.issue-5.xml>

[Reviewed earlier]

### **Annals of Internal Medicine**

November 2025 Volume 178, Issue 11

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

### **Artificial Intelligence – An International Journal**

Volume 349 December 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/349/suppl/C>

[New issue; No digest content identified]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 06 Dec 2025)

[No new digest content identified]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 06 Dec 2025)

[No new digest content identified]

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 06 Dec 2025)

[No new digest content identified]

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 06 Dec 2025)

[No new digest content identified]



## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 06 Dec 2025)

[No new digest content identified]

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 06 Dec 2025)

No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 06 Dec 2025)

*Articles*

**[The public health impact of extending the catch-up nonavalent human papillomavirus vaccination program to 2028 in Japan: a model-based study](#)**

Ibrahim Diakite

Keisuke Tobe

Taizo Matsuki

Research Open access 06 December 2025

**[Is the domestic bivalent HPV vaccine cost-effective compared with quadrivalent or nine-valent HPV vaccines in the context of cervical cancer screening? A modeling study](#)**

Liangwen Zhang

Yanhui Zhang

Ya Fang

Research Open access 04 December 2025

**[HPV vaccine knowledge gaps and vaccination intent: a cross-sectional study of vocational students in Southern Xinjiang of China in 2023](#)**

Guligeina Abudurexiti

Kadeliya Muhetaer

Remila Rezhake

Research Open access 03 December 2025

## **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 06 Dec 2025)

[No new digest content identified]

## **BMJ Evidence-Based Medicine**

October 2025 - Volume 30 - 5

<https://ebm.bmj.com/content/30/5>

[Reviewed earlier]

## **BMJ Global Health**

November 2025 - Volume 10 - 11

<https://gh.bmj.com/content/10/11>

[Reviewed earlier]

### **Bulletin of the Atomic Scientists**

DIGITAL MAGAZINE - September 2025

<https://thebulletin.org/magazine/2025-09/#post-heading>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 103, Number 11, November 2025, 641-752

<https://www.who.int/publications/journals/bulletin/>

Article

#### **[Digital transformation and the Immunization agenda 2030](#)**

[Mickey Chopra](#) a,✉, [Christopher Wolff](#) b, [Zulfiqar A Bhutta](#) c, [Francesco Checchi](#) d, [Mira Johri](#) e, [Thabani Maphosa](#) f, [Barni Nor](#) g, [Katherine L O'Brien](#) h, [Ephrem Tekle Lemango](#) i

PMCID: PMC12665274 PMID: 41328208

Digital transformation is the intentional, systematic implementation of integrated digital applications that change how governments plan, execute, measure and monitor programmes. This transformation can accelerate progress towards the Immunization agenda 2030, which aims to ensure that everyone, everywhere, at every age, fully benefits from vaccines.<sup>1</sup> Here we describe how digital transformation can help achieve equitable immunization outcomes, and outline recommendations for governments and global partners to ensure that children in low- and middle-income countries benefit fairly.

### **Cell**

Oct 30, 2025 Volume 188 Issue 22 p6105-6390

<https://www.cell.com/cell/current>

[Reviewed earlier]

### **Cell and Gene Therapy Insights**

May 2025 Issue Volume 11 Issue 4

<https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4>

[Reviewed earlier]

### **Child Care, Health and Development**

Volume 51, Issue 6 November 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 118, Issue 5 Pages: 969-1224 November 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[New issue; No digest content identified]

### **Clinical Therapeutics**

November 2025 Volume 47 Issue 11 p957-1088

<http://www.clinicaltherapeutics.com/current>  
[Reviewed earlier]

### **Clinical Trials**

Volume 22 Issue 5, October 2025  
<https://journals.sagepub.com/toc/ctja/22/5>  
[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>  
[Accessed 06 Dec 2025]  
[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 158 November 2025  
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/158/suppl/C>  
[Reviewed earlier]

### **The CRISPR Journal**

Volume 8, Issue 5 / October 2025  
<https://www.liebertpub.com/toc/crispr/8/5>  
[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 13, Issue 1 December 2025  
<https://link.springer.com/journal/40142/volumes-and-issues/13-1>  
[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 41, Issue 3 2025  
<https://www.tandfonline.com/toc/icmo20/current>  
[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

October 2025 - Volume 38 - Issue 5  
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>  
*PAEDIATRIC AND NEONATAL INFECTIONS*  
[Reviewed earlier]

### **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>  
[Accessed 06 Dec 2025]  
[No new digest content identified]

**Cytotherapy**

November 2025 Volume 27 Issue 1271 p121-1362

<https://www.isct-cytotherapy.org/current>

[Reviewed earlier]

**Developing World Bioethics**

Volume 25, Issue 3 Pages: 165-252 September 2025

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

**Development in Practice**

Volume 35, Issue 5, 2025

<https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList>

[Reviewed earlier]

**Development Policy Review**

Volume 43, Issue 5 September 2025

<https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList>

[Reviewed earlier]

**Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

**Disasters**

Volume 50, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

**eBioMedicine**

Volume 121 November 2025

<https://www.sciencedirect.com/journal/ebiomedicine/vol/121/suppl/C>

[Reviewed earlier]

**EMBO Reports**

Volume 26 Issue 21 6 November 2025

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

**Emerging Infectious Diseases**

Volume 31, Number 10—October 2025

<http://wwwnc.cdc.gov/eid/>  
[Reviewed earlier]

### **Epidemics**

Volume 52 September 2025

<https://www.sciencedirect.com/journal/epidemics/vol/52/suppl/C>  
[Reviewed earlier]

### **Epidemiology and Infection**

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>  
[Reviewed earlier]

### **Ethics & Human Research**

Volume 47, Issue 5 Pages: 1-43 September–October 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>  
[Reviewed earlier]

### **Ethics & International Affairs**

Volume 39 - Issue 2 - Summer 2025

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue> [  
***Roundtable: Global Governance in Hard Times***  
[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 33 2025

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>  
[Reviewed earlier]

### **The European Journal of Public Health**

Volume 35, Issue 5, October 2025

<https://academic.oup.com/eurpub/issue/35/5>  
[Reviewed earlier]

### **Expert Review of Vaccines**

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>  
[Reviewed earlier]

### **Foreign Affairs**

November/December 2025 Volume 104, Number 6

<https://www.foreignaffairs.com/issues/2025/104/5>  
[Reviewed earlier]

## **Forum for Development Studies**

Volume 52, 2025 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

***The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities***

[Reviewed earlier]

## **Frontiers in Genetics**

<https://www.frontiersin.org/journals/genetics>

[Accessed 06 Dec 2025]

[No new digest content identified]

## **Frontiers in Genome Editing**

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 06 Dec 2025]

[No new digest content identified]

## **Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 06 Dec 2025]

[No new digest content identified]

## **Gene Therapy – Nature**

Volume 32 Issue 5, October 2025

<https://www.nature.com/gt/volumes/32/issues/5>

[Reviewed earlier]

## **Genetics in Medicines**

Volume 27, Issue 12 December 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65>

[Reviewed earlier]

## **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 06 Dec 2025]

[No new digest content identified]

## **Global Health Action**

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

August 2025 | Volume 13 | Number 1

<http://www.ghspjournal.org/content/current>  
[Reviewed earlier]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>  
[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)  
[Accessed 06 Dec 2025]  
[No new digest content identified]

### **Global Public Health**

Volume 20, Issue 1 (2025)  
<http://www.tandfonline.com/toc/rgph20/current>  
[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>  
[Accessed 06 Dec 2025]  
[No new digest content identified]

### **Health and Human Rights**

Volume 27, Issue 1, June 2025  
<https://www.hhrjournal.org/volume-27-issue-1-june-2025/>  
***SPECIAL SECTION - FIGHT FOR RIGHTS VIEWPOINT SERIES***  
[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 20 - Issue 4 - October 2025  
<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>  
[Reviewed earlier]

### **Health Policy and Planning**

Volume 40, Issue 10, November 2025  
<https://academic.oup.com/heapol/issue/40/10>  
[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>  
[Accessed 06 Dec 2025]  
[No new digest content identified]

### **Human Gene Therapy**

Volume 36, Issue 21-22 / November 2025  
<https://www.liebertpub.com/toc/hum/36/21-22>



[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

[Accessed 06 Dec 2025]

*Featured Publications*

[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 21 Issue 1, 2025

<https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

### **Immunity**

Nov 11, 2025 Volume 58 Issue 11 p2609-2916

<https://www.cell.com/immunity/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 06 Dec 2025]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 06 Dec 2025]

[No new digest content identified]

### **International Health**

Volume 17, Issue 6, November 2025

<https://academic.oup.com/inthealth/issue/17/6>

[Reviewed earlier]

### **International Human Rights Law Review**

Volume 14 (2025): Issue 1 (Jun 2025)

<https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml>

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 12 No. 12 (2025): December 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/131>

[Reviewed earlier]

## **International Journal of Epidemiology**

Volume 54, Issue 5, October 2025

<https://academic.oup.com/ije/issue/54/5>

[Reviewed earlier]

## **International Journal of Human Rights in Healthcare**

Volume 18, Issue 4 22 October 2025

<https://www.emerald.com/ijhrh/issue/18/4>

*Table of contents*

[Reviewed earlier]

## **JAMA**

December 2, 2025, Vol 334, No. 21, Pages 1867-1960

<https://jamanetwork.com/journals/jama/currentissue>

*M Viewpoint*

### **America's Vaccine Policy Whiplash—Finding the Way Forward**

Mark C. Navin, PhD, HEC-C; Lainie F. Ross, MD, PhD

JAMA. 2025;334(21):1877-1878. doi:10.1001/jama.2025.19088

This Viewpoint discusses the effect of changes in vaccine policies on public health and strategies for reversing the policies' direction.

### **Potential Repercussions of Eliminating Mandatory Vaccination in Florida**

Sten H. Vermund, MD, PhD

JAMA. 2025;334(21):1879-1880. doi:10.1001/jama.2025.19510

This Viewpoint discusses the potential repercussions of eliminating mandatory vaccination in Florida, including surges in outbreaks, hospitalizations, and preventable deaths.

### **The Measles Resurgence**

Jane R. Zucker, MD, MSc

JAMA. 2025;334(21):1881-1882. doi:10.1001/jama.2025.19138

This Viewpoint discusses vaccination levels and the resurgence of measles in the US.

## **JAMA Health Forum**

November 2025, Vol 6, No. 11

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

## **JAMA Pediatrics**

November 2025, Vol 179, No. 11, Pages 1139-1248

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

## **JBIR Evidence Synthesis**

October 2025 - Volume 23 - Issue 10

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Adolescent Health**

November 2025 Volume 77 Issue 5 p797-1008

<https://www.jahonline.org/current>

[Reviewed earlier]

**Journal of Artificial Intelligence Research**

Vol. 83 (2025)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

**Journal of Bioethical Inquiry**

Volume 22, Issue 3 September 2025

<https://link.springer.com/journal/11673/volumes-and-issues/22-3>

[Reviewed earlier]

**Journal of Community Health**

Volume 50, Issue 6 December 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-6>

[Reviewed earlier]

**Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

**Journal of Development Economics**

Volume 178 January 2026

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/178/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 20 Issue 5, December 2025

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

November 2025 - Volume 79 - 11

<https://jech.bmj.com/content/79/11>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 18, Issue 3 September 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 21, Issue 2 (2025)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 36, Number 3, August 2025

<https://muse.jhu.edu/issue/55342>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 27, Issue 5 October 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-5>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 23, Issue 4 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of International Development**

Volume 37, Issue 8 Pages: 1-1697 November 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

**Journal of Law, Medicine & Ethics**

Volume 53 - Issue 3 - Fall 2025

<https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue>

***Public Health, Markets, and Law***

[Reviewed earlier]

**Journal of Medical Ethics**

December 2025 - Volume 51 - 12

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 12, Issue 3 (2025)  
<https://institutionalrepository.aah.org/jpcrr/>  
[Reviewed earlier]

**The Journal of Pediatrics**

Volume 286 November 2025  
<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/286/suppl/C>  
[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

Volume 18, 2025 Issue 1  
<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>  
[Reviewed earlier]

**Journal of Public Health Management & Practice**

November/December 2025 - Volume 31 - Issue 6  
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>  
[Reviewed earlier]

**Journal of Public Health Policy**

Volume 46, Issue 4 December 2025  
<https://link.springer.com/journal/41271/volumes-and-issues/46-4>  
[Reviewed earlier]

**Journal of the Royal Society – Interface**

November 2025 Volume 22 Issue 232  
<https://royalsocietypublishing.org/toc/rsif/current>  
[Reviewed earlier]

**Journal of Travel Medicine**

Volume 32, Issue 6, August 2025  
<https://academic.oup.com/jtm/issue>  
[Reviewed earlier]

**Journal of Virology**

Volume 99 • Number 10 • October 2025  
<http://jvi.asm.org/content/current>  
[Reviewed earlier]

**The Lancet**

Dec 06, 2025 Volume 406 Number 10520 p2601-2726  
<https://www.thelancet.com/journals/lancet/issue/current>  
[New issue; No digest content identified]

**The Lancet Child & Adolescent Health**

Dec 2025 Volume 9 Number 12 p817-890, e24-e27

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

**Lancet Digital Health**

Sep 2025 Volume 7 Number 9

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

**Lancet Global Health**

Dec 2025 Volume 13 Number 12 e1991-e2179

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Nov 2025 Volume 25 Number 11 p1159-1264, e621-e675

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Nov 2025 Volume 10 Number 11 e890-e1005

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Nov 2025 Volume 13 Number 11 p951-1040, e56-e58

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 29, Issue 10 October 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-10>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 45 Issue 8, November 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 103, Issue 3 Pages: 639-939 September 2025

<https://onlinelibrary.wiley.com/toc/14680009/current>  
[Reviewed earlier]

### **Molecular Therapy**

Nov 05, 2025 Volume 33 Issue 11 p5283-5908  
<https://www.cell.com/molecular-therapy/current>  
[Reviewed earlier]

### **Nature**

Volume 648 Issue 8092, 4 December 2025  
<https://www.nature.com/nature/volumes/647/issues/8092>  
*Editorial* 02 Dec 2025

#### **[Don't downplay problems of bullying and harassment in academia](#)**

The United Kingdom, like all countries, must prioritize a supportive research culture as an essential ingredient in research excellence

### **Nature Biotechnology**

Volume 43 Issue 11, November 2025  
<https://www.nature.com/nbt/volumes/43/issues/11>  
[Reviewed earlier]

### **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>  
(Accessed 06 Dec 2025)  
[Reviewed earlier]

### **Nature Genetics**

Volume 57 Issue 11, November 2025  
<https://www.nature.com/ng/volumes/57/issues/11>  
Reviewed earlier]

### **Nature Human Behaviour**

Volume 9 Issue 10, October 2025  
<https://www.nature.com/nathumbehav/volumes/9/issues/10>  
[Reviewed earlier]

### **Nature Medicine**

Volume 31 Issue 11, November 2025  
<https://www.nature.com/nm/volumes/31/issues/11>  
[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 24 Issue 10, October 2025  
<https://www.nature.com/nrd/volumes/24/issues/10>



[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 26 Issue 11, November 2025

<https://www.nature.com/nrg/volumes/26/issues/11>

[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 25 Issue 10, October 2025

<https://www.nature.com/nri/volumes/25/issues/1>

[Reviewed earlier]

### **New England Journal of Medicine Volume**

Volume 393 No. 22 December 4, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

#### **The New U.S. Global Health Strategy — A Reset of America's Health Cooperation**

J. Ratevosian and Others

The U.S. administration recently unveiled its new approach to global health. A retreat from multilateralism, a geopolitical emphasis, and rushed transitions could threaten progress.

*Special Article*

#### **Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026**

J. Scott and Others

### **NEJM Evidence**

Volume 4 No. 9 September 2025

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[Reviewed earlier]

### **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 06 Dec 2025]

[No new digest content identified]

### **Pediatrics**

Volume 156, Issue 5 November 2025

<https://publications.aap.org/pediatrics/issue/156/5>

*From the American Academy of Pediatrics*

[Reviewed earlier]

### **PharmacoEconomics**

Volume 43, Issue 12 December 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-12>  
[Reviewed earlier]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>  
(Accessed 06 Dec 2025)

#### **[How to integrate patient and carer perspectives, methodological rigor, and ethics into biomedical research funding](#)**

Hella Lichtenberg, Christina Müller, Henk Lindeman, Leila Ali, Anja Minheere, Monique van den Eijnden, Ulrich Dirnagl

Community Page | published 04 Dec 2025 PLOS Biology  
<https://doi.org/10.1371/journal.pbio.3003551>

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>  
(Accessed 06 Dec 2025)  
[No new digest content identified]

### **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)  
(Accessed 06 Dec 2025)  
[No new digest content identified]

### **PLoS Medicine**

<https://journals.plos.org/plosmedicine/>  
(Accessed 06 Dec 2025)  
[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>  
(Accessed 06 Dec 2025)  
[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>  
[Accessed 06 Dec 2025]

#### **[Awareness, knowledge, and beliefs about Human Papillomavirus and its vaccine among Egyptian medical students: A cross-sectional national study](#)**

Muhammad Elmanzlawey, Mohamed Terra, Mohamed Baklola, Yara Ahmed, Mariam Abuelela, Ibrahim Nouredin Al-Kurd, Abdel-Hady El-Gilany

Research Article | published 05 Dec 2025 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0337411>

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>  
[Accessed 06 Dec 2025]  
[No new digest content identified]

## **PNAS - Proceedings of the National Academy of Sciences of the United States**

December 2, 2025 vol. 122 no. 48

<https://www.pnas.org/toc/pnas/122/48>

*Research Article* November 24, 2025 Inaugural Article

### **Using a mental model approach to undercut the effects of exposure to mRNA vaccination misconceptions: Two randomized trials**

Although messenger RNA (mRNA) technology revolutionized vaccine creation, its use is threatened by unwarranted fear that DNA left over from the vaccine manufacturing process could integrate into recipients' DNA, increasing cancer and heritable risks. ...

Kathleen Hall Jamieson, et al.

## **PNAS Nexus**

Volume 4, Issue 11, November 2025

<https://academic.oup.com/pnasnexus/issue/4/11>

[Reviewed earlier]

## **Prehospital & Disaster Medicine**

Volume 40 - Issue 5 - October 2025

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

## **Preventive Medicine**

Volume 200 November 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/200/suppl/C>

[Reviewed earlier]

## **Proceedings of the Royal Society B**

November 2025 Volume 292 Issue 2058

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

## **Public Health**

Volume 246 September 2025

<https://www.sciencedirect.com/journal/public-health/vol/246/suppl/C>

[Reviewed earlier]

## **Public Health Ethics**

Volume 18, Issue 2, July 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Genomics**

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

**Public Health Reports**

Volume 140 Issue 5-6, Sep-Oct/Nov-Dec 2025

<https://journals.sagepub.com/toc/phrg/140/5-6>

[Reviewed earlier]

**Qualitative Health Research**

Volume 35 Issue 13, November 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

**Research Ethics**

Volume 21 Issue 4, October 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

**Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 06 Dec 2025]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

[No new digest content identified]

**Risk Analysis**

Volume 45, Issue 11 Pages: 3331-4076 November 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

**Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 06 Dec 2025]

[No new digest content identified]

**Royal Society Open Science**

November 2025 Volume 12 Issue 11

<https://royalsocietypublishing.org/toc/rsos/current>  
[Reviewed earlier]

## **Science**

Volume 390| Issue 6777| 4 Dec 2025  
<https://www.science.org/toc/science/current>  
*Editorial*

### **Accelerating science with AI**

BY Darío Gil, Kathryn A. Moler  
25 Nov 2025:

By successfully integrating artificial intelligence (AI) into research workflows, researchers could substantially increase scientific productivity. Last week's announcement from the White House of the US Genesis Mission sparks a critical conversation about how to realize this potential. That discussion should center on two parallel efforts—creating the integrated infrastructure, from data and algorithms to hardware and agentic control, needed to apply AI to speed up research; and determining the policies and resources that empower scientists to fuel the feedback loop of scientific advancement and AI innovation...

## **Science and Engineering Ethics**

Volume 31, Issue 6 December 2025  
<https://link.springer.com/journal/11948/volumes-and-issues/31-6>  
[Reviewed earlier]

## **Science Translational Medicine**

Volume 17| Issue 827| 3 Dec 2025  
<https://www.science.org/toc/stm/current>  
[New issue; No digest content identified]

## **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>  
[Accessed 06 Dec 2025]  
[No new digest content identified]

## **Social Science & Medicine**

Volume 386 December 2025  
<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/386/suppl/C>  
[Reviewed earlier]

## **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>  
[Accessed 06 Dec 2025]  
[No new digest content identified]

## **Theoretical Medicine and Bioethics**

Volume 46, Issue 6 December 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-6>

[Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 67 September–October 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/67/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 30, Issue 11 Pages: 1145-1260 November 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

### **Vaccine**

Volume 68 5 December 2025

<https://www.sciencedirect.com/journal/vaccine/vol/67/suppl/C>

[Reviewed earlier]

### **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 06 Dec 2025]

[No new digest content identified]

### **Value in Health**

November 2025 Volume 28 Issue 11 p1601-1784

<https://www.valueinhealthjournal.com/current>

Reviewed earlier]

### **World Development**

Volume 196 December 2025

<https://www.sciencedirect.com/journal/world-development/vol/196/suppl/C>

[New issue; No digest content identified]

.....

.....

### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....

.....

### ***Pre-Print Servers***

## arXiv

<https://arxiv.org/>

[Accessed 06 Dec 2025]

*[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Computational Engineering, Finance, and Science; General Literature; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]*

[No new digest content identified]

## Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 06 Dec 2025]

*[Filter: All articles]*

[No new digest content identified]

## medRxiv

<https://www.medrxiv.org/content/early/recent>

[Accessed 06 Dec 2025]

*[Filter: All articles]*

### **Pandemic-Potential Viruses are a Blind Spot for Frontier Open-Source LLMs**

Laura Luebbert, Yasha Ektefaie, Arya S. Rao, Colby Wilkason, Dolo Nosamiefan, Olivia Achonduh-Atijegbe, Harouna Soumare, Adefoye Precious Adebayo, Olufemi Olulaja, Judith Amadi, Nicholas Oyejide, Funmilayo Olayiwola, Etim Henshaw, Yusuf Okocha, Nkechinyere Nwachukwu, Elechi Friday Ewah, Sylvanus Okoro, Ebenezer Nwakpakpa, Peter Okokhere, Kelly Iraoyah, Joseph Okoeguale, Ireti Dada, Andy Burris, Karlie Zhao, Ellory Laning, Chase van Amburg, Paul Cronan, Ben Fry, Christian Happi, Al Ozonoff, Pardis C. Sabeti

medRxiv 2025.12.04.25341642; doi: <https://doi.org/10.64898/2025.12.04.25341642>

### **Human milk oligosaccharides, oral rotavirus vaccine seroconversion, and rotavirus gastroenteritis risk in a vaccinated birth cohort**

Rebecca Judith Rubinstein, Nadja Alexandra Vielot, Jessie K Edwards, Yaoska Reyes, Fredman Gonzalez, Cristhian Toval-Ruiz, Lester Gutierrez, Slavica Mijatovic-Rustempasic, Samuel Vilchez, Robert S Sandler, Lakshmanane Premkumar, Lars Bode, Sylvia Becker-Dreps, Filemon Bucardo

medRxiv 2025.12.04.25341660; doi: <https://doi.org/10.64898/2025.12.04.25341660>

### **Predictors of COVID-19 Vaccine Hesitancy and Adverse Events following COVID-19 vaccination among People on Anti-retroviral therapy in Nigeria**

Victoria Etuk, Oluwafemi Omonijo, Charity Sanni, Stella Ijioma, Alash'le Abimiku, Evaezi Okpokoro

medRxiv 2025.12.05.25341692; doi: <https://doi.org/10.64898/2025.12.05.25341692>

### **Uptake and Determinants of Hepatitis B Vaccination among Health Laboratory Practitioners in Tertiary Hospitals in Dar es Salaam, Tanzania: A Cross-Sectional Study.**

Seleman Said, Mary Migiro, Dominic Renatus, Raidah R Gangji, Lilian Nkinda, Upendo Kibwana, Frank Msafiri, Doreen Kamori, Agricola Joachim, Joel Manyahi, Mtebe V Majigo, Salim S. Masoud

medRxiv 2025.12.03.25341607; doi: <https://doi.org/10.64898/2025.12.03.25341607>

### **Vaccination of adolescent girls against Human Papillomavirus (HPV) in Embakasi West, Kenya: the role of family ties and value systems in decision making**

Wanjiru S. Ng'ang'a, Solomon K. Cheboi, Peter Omemo, Apollo O. Maima

medRxiv 2025.12.01.25341402; doi: <https://doi.org/10.64898/2025.12.01.25341402>

### **Limitations of Disease X vaccine efficacy and safety clinical trials**

Julien Flaig, Nicolas Houy

medRxiv 2025.10.11.25337791; doi: <https://doi.org/10.1101/2025.10.11.25337791> Revision

### **Public health benefits of maternal influenza vaccination among pregnant women and infants <6 months in the United States, 2011–2020**

Sinead E. Morris, Alissa O'Halloran, Devi Sundaresan, Samantha M. Olson, Jessie R. Chung, Sascha Ellington, Catherine H. Bozio, A. Danielle Iuliano, Matthew Biggerstaff, Carrie Reed

medRxiv 2025.12.01.25339330; doi: <https://doi.org/10.64898/2025.12.01.25339330>

### **Trends and Predictors of Measles Immunisation Inequalities Among Children Aged 12–23 Months in the Philippines, 2008–2022**

John Carlo Lorenzo, Md Irteja Islam, Carla Ante-Orozco, Erin Mathieu

medRxiv 2025.12.01.25341428; doi: <https://doi.org/10.64898/2025.12.01.25341428>

### **Safety and immunogenicity of a quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with a quadrivalent meningococcal conjugate vaccine (Menactra®): a study protocol of a randomized non-inferiority trial in Mali**

Simonetta Viviani, Ruoyu Hu, Samba O Sow, Milagritos D Tapia, Fadima Cheick Haidara, Fatoumata Diallo, Youssouf Traore, Awa Traoré, Mamoudou Kodio, Lei Shi

medRxiv 2025.11.28.25341186; doi: <https://doi.org/10.1101/2025.11.28.25341186>

### **LEAP-InovAND a multiscale resource to explore genetics, brain imaging and clinical data in autism**

M. Fleury, Z. M. Mougin, C. S. Leblond, F. Cliquet, A. Mathieu, B. Oakley, A. Maruani, J.-M. de Saint Agathe, S. Korkmaz, R. Holt, A. Vitrac, F. Amsellem, A. Batut, G. Botton-Amiot, T. Rolland, E. Barthome, R. Bonicel, A. Beggiato, N. Lemièrre, A.-C. Tabet, J. Levy, C. Lehoucq, A. Ayrolles, C. A. Moreau, L. Colomar Molla, R. Toro, N. Traut, A. Lefebvre, D. L. Floris, G. Dumas, G. Huguet, S. Bonnot-Briey, F. Campana, J. Van Gils, V. Wang, J. Buratti, L. Jornea, S. Loiodice, S. Forlani, S. Fournier, D. Bacq-Daïan, R. Olaso, V. Meyer, B. Fin, AIMS2-2-Trials AREps group, A. Ghosh, M. Doherty, S. Li-Williams, InovAND group, EU-AIMS/AIMS-2-Trials LEAP group, J.-F. Deleuze, A. M. Persico, M. Leboyer, C. Gillberg, S. Bölte, C. Beckmann, C. Ecker, E. Jh Jones, V. Warriier, S. Baron-Cohen, T. Charman, E. Loth, J. K. Buitelaar, J. Tillmann, R. Delorme, D. Murphy, T. Bourgeron

medRxiv 2025.11.24.25340858; doi: <https://doi.org/10.1101/2025.11.24.25340858> Revision

### **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 06 Dec 2025]

*Study Protocol Open Access*

### **Study protocol: Effectiveness of the maternal RSVpreF vaccine by virus type**

[version 1; peer review: awaiting peer review]

Anna Mensah, et al.

*Abstract*



### *Background*

Respiratory syncytial virus (RSV) is a virus with two antigenic types, A and B, that cause significant morbidity and mortality in infants globally. A recently developed maternal vaccination based on the prefusion F protein ("RSVpreF") could have a significant impact on disease burden, if introduced globally. Whether or not the effectiveness of this vaccine is affected by circulating viral genomic variability is currently unknown.

### *Objectives*

To examine whether the vaccine effectiveness of maternal RSVpreF administration in preventing hospitalisation in infants is affected by RSV type or lineage.

\* \* \* \*

### **Think Tanks**

**Brookings** [to 06 Dec 2025]

<http://www.brookings.edu/>

*Research, Events*

*Regulatory Policy*

**[Tracking regulatory changes in the second Trump administration](#)**

December 3, 20

**Center for Global Development** [06 Dec 2025]

<https://www.cgdev.org/>

*All Research*

*Research, Events*

*No new digest content identified.*

**Chatham House** [to 06 Dec 2025]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [06 Dec 2025]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [06 Dec 2025]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

**McKinsey Global Institute** [to 06 Dec 2025]

<https://www.mckinsey.com/mgi/overview>

*Featured Research*

*No new digest content identified.*

**ODI** [Overseas Development Institute] [to 06 Dec 2025]

<https://odi.org/en/publications/>

*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 06 Dec 2025]

<https://www.pewresearch.org/>

*Latest Publications*

*fact sheet* Dec 4, 2025

**Public Trust in Government: 1958-2025**

While trust in government has been low for decades, the current measure is one of the lowest in the nearly seven decades since the question was first asked by the National Election Study, and it is lower than it was last year (22%).

*short reads* Dec 1, 2025

**Where most people trust others and where they don't around the world**

Trust tends to be higher in the high-income countries surveyed than in the middle-income ones.

**Rand** [to 06 Dec 2025]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*Research* Dec 1, 2025

**Strategies to Improve Detection of Novel Pandemic Pathogens: Cost Versus Detection Performance for Promising Pathogen-Agnostic Detection Workflows**

To inform decisions that enable the next generation of biosurveillance systems to rapidly detect outbreaks of novel pathogens, the authors evaluated the cost and detection performance of three promising pathogen-agnostic detection strategies.

*Research* Dec 1, 2025

**Mapping the Informal Bioeconomy: Assessing the Current Landscape and Opportunities for Reinforcing Biosafety and Biosecurity**

The rapid growth of biotechnology research has resulted in a powerful ecosystem known as the bioeconomy. In this report, the authors seek to map and evaluate the informal bioeconomy from a biosecurity perspective.

**Urban Institute** [to 06 Dec 2025]

<https://www.urban.org/research>

*New Research Publications - Selected*

*No new digest content identified.*

**World Economic Forum** [to 06 Dec 2025]

<https://agenda.weforum.org/press/>

*Media [Selected]*

*No new digest content identified.*

.....

.....

## ***Public Consultations/Call for Inputs/Call for Papers***

### **Malaria: Developing Drugs for Treatment; Draft Guidance for Industry; Availability**

A Notice by the Food and Drug Administration on 09/23/2025. **Comment period ends 12/22/2025.**

Docket No. FDA-2025-D-0918

#### ***Background***

FDA is announcing the availability of a draft guidance for industry entitled "Malaria: Developing Drugs for Treatment." The purpose of this draft guidance is to assist sponsors in the overall development program for drug and biological products for the treatment of malaria, caused by clinically relevant Plasmodium species. Specifically, this draft guidance is intended to serve as a focus for continued discussions on the design of malaria treatment trials among the Agency, pharmaceutical sponsors, the academic community, and the public.

\* \* \* \*

#### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

\* \* \* \*  
\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable

development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#) and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*